Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 3447. Отображено 198.
27-08-2016 дата публикации

СОЕДИНЕНИЯ И КОМПОЗИЦИИ С ПОЛИГЛИЦЕРИНОМ

Номер: RU2595877C2

Группа изобретений относится к области косметической промышленности, а именно к загустителю на основе полиглицерина, включающему одно или несколько соединений, характеризующихся наличием узловой структуры, которая представляет собой остаток полинуклеофила, полученный из метилглюкозида, одной или нескольких групп (поли)глицерина со средней степенью полимеризации от более 3 до менее 11 и одной или нескольких гидрофобных функциональных групп, представляющих собой 8-гептадеценил, где каждая из одной или более указанных групп (поли)глицерина связана с указанной узловой структурой через связывающую группу, представляющую собой -O-, и каждая из одной или более указанных гидрофобных функциональных групп независимо связана с указанной узловой структурой через связывающую группу, представляющую собой -С(O)O-, и при этом среднее число гидрофобных групп на первичную связывающую группу составляет 0,35 или более, кроме того, в одном из вариантов, указанный загуститель имеет средний показатель гидрофильности ...

Подробнее
10-08-2000 дата публикации

ГЛЮКОЗАМИНОВЫЕ ДИСАХАРИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Номер: RU2154068C2

FIELD: medicine. SUBSTANCE: described are β(1→6) glucosamine disaccharides of formula I: wherein 83909 гс ПЧ сэ (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ "” 2 154 068 (51) МПК? (13) С2 С 07 Н 13/06, 15/04, Аб1 К 31/70, А 61Р 35/00, 37/02 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 96113100/04, 17.11.1994 (24) Дата начала действия патента: 17.11.1994 (30) Приоритет: 17.11.1993 ЕР 93203223.8 (46) Дата публикации: 10.08.2000 (56) Ссылки: ЗИ 1652319 АЛ, 1991. ЕР 0192296 АЛ, 1986. ($ 4912094 А, 1990. (85) Дата перевода заявки РСТ на национальную фазу: 17.06.1996 (86) Заявка РСТ: ЕР 94/03852 (17.11.1994) (87) Публикация РСТ: М/О 95/14026 (26.05.1995) (98) Адрес для переписки: 129010, Москва, ул. Большая Спасская 25, стр.3, ООО "Городисский и Партнеры", Лебедевой Н.Г. (71) Заявитель: ЛАБОРАТУАР ОМ С.А. (СН), ДОИЧЕ ОМ АРЦНАИМИТТЕЛЬ ГМБХ (0Е) (72) Изобретатель: Джон Гуинфор ДЭВИС (СВ), Жак БАУЕР (СН), Пьер ХИРТ (СН), Адриан ШУЛЬТЕСС (СН) (73) Патентообладатель: ЛАБОРАТУАР ОМ С.А. (СН), ДОИЧЕ ОМ АРЦНАИМИТТЕЛЬ ГМБХ (0Е) (54) ГЛЮКОЗАМИНОВЫЕ ДИСАХАРИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (57) Изобретение относится К В(1>б)глюкозаминовым — дисахаридам, имеющим общую формулу |, где Кл, К>, Въ, К4, К, В, КВ, Кё имеют значения, указанные в формуле изобретения, а также к способу их получения и к фармацевтической КОМПОЗИЦИИ, включающей в качестве активного ингредиента эти дисахариды. Соединения по изобретению могут быть использованы при лечении или профилактике, как иммуномодулирующие, противоопухолевые агенты и вакцины. 3 с. и 30 з.п.ф-лы, 19 ил., компоненты 13 табл. ® ес Молекулясньый вес (4) Маесшаг Меч =1055.35 тТочкая масса Ехас{ Мазз =1054 Маесуаг Рога «СЗаНомаОттР ‚Молвку ярная ‘ферчуия маесч!аг Сотрозтоп =С 59.1 9.46% М 2.65% О 25.17% Р 2.93% Молехулярный сосшав Фиг. 1 2154068 С2 КО 83909 гс ПЧ сэ КУЗЗАМ АСЕМСУ ГОК РАТЕМТ$ АМО ТКАОЕМАКК$ 12) АВЗТКАСТ ОЕ 1МУЕМТОМ (19) ВИ "” 2 154 068 С 07 Н 13/06, 15/04, А 61 К (51) ...

Подробнее
10-02-2016 дата публикации

ИЗОТИАЗОЛОПИРИДИН-2-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ФАРМАЦЕВТИЧЕСКИХ СРЕДСТВ

Номер: RU2014129903A
Принадлежит: Санофи

1. Соединение формулы I, в любой из его стереоизомерных форм или смеси стереоизомерных форм в любом отношении, или его фармацевтически приемлемая соль,в которойX выбран из ряда, состоящего из =N-и =N(O)-;R1, R2 и R3 независимо друг от друга выбраны из ряда, состоящего из водорода, галогена, (C-C)-алкила,(C-C)-алкил-O-, нитро, циано,(C-C)-алкил-O-C(O)-, R4-N(R5)-C(O)- и R6-N(R7)-S(O)-;R4 выбран из ряда, состоящего из водорода, (C-C)-алкила,(C-C)-циклоалкила,(C-C)-циклоалкил-(C-C)-алкила-, фенила, фенил-(C-C)-алкила-, Het1 и Het1-(C-C)-алкила-, причем Het1 в случае необходимости замещен одним или более одинаковыми или разными заместителями R8;R5, R6 и R7 независимо друг от друга выбраны из ряда, состоящего из водорода, (C-C)-алкила,(C-C)-циклоалкила и(C-C)-циклоалкил-(C-C)-алкила-;R8 выбран из ряда, состоящего из галогена, (C-C)-алкила, гидрокси, оксо,(C-C)-алкил-O- и циано;R10 выбран из ряда, состоящего из водорода, (C-C)-алкила,(C-C)-циклоалкила,(C-C)-циклоалкил-(C-C)-алкила- и(C-C)-алкил-O-(C-C)-алкила-, при условии, что R10 может быть только водородом, если X обозначает =N(O)-;R11 выбран из ряда, состоящего из (C-C)-алкила, который в случае необходимости замещен одним или более одинаковыми или разными заместителями R12,(C-C)-циклоалкила, который в случае необходимости замещен одним или более одинаковыми или разными заместителями R13, и Het2, который в случае необходимости замещен одним или более одинаковыми или разными заместителями R14, и причем Het2 присоединен через кольцевой атом углерода;или группы R10 и R11, вместе с атомом азота, несущим их, образуют 4-12-членный моноциклический или бициклический, насыщенный или частично ненасыщенный гетероцикл, который, в дополнение к атому азота, несущему R10 и R11, включает 0, 1 или 2 дополнительных кольцевых гетероатома, выбранных из ряда, состоящего из азота, кислорода и серы, который в случае необходимости замещен на кольцевых атомах углерода одним ил РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07D 513/04 (13) 2014 ...

Подробнее
20-05-2013 дата публикации

СОЕДИНЕНИЯ И КОМПОЗИЦИИ С ПОЛИГЛИЦЕРИНОМ

Номер: RU2011146127A
Принадлежит:

... 1. Способ получения полиглицериновой композиции, включающий взаимодействие одного или более глицериновых мономеров с инициатором полимеризации формулы:где Z представляет собой узловую структуру, не являющуюся полинуклеофильным остатком, полученным из сорбитана;каждая Nu представляет собой полинуклеофильную группу;каждая Hphob представляет собой гидрофобную группу;каждая L' представляет собой первичную связывающую группу;h принимает значения от 1 до 12;b принимает значения от 1 до 11;h+b равно, по меньшей мере, 4; иh/h+b составляет более 0,35.2. Способ по п.1, где указанный инициатор полимеризации является эфиром полиола, выбранным из группы, состоящей из диэфиров глюкозидов, диэфиров диглицерина, диэфиров триглицерина и сочетания двух или более из этих веществ.3. Способ по п.2, где указанный один или более глицериновых мономеров выбран из группы, состоящей из глицерина карбоната, глицида, C-Cсложного моноэфира глицеринкарбоната, C-Cсложного моноэфира глицида и сочетания двух или более из ...

Подробнее
20-05-2013 дата публикации

СОЕДИНЕНИЯ И КОМПОЗИЦИИ С ПОЛИГЛИЦЕРИНОМ

Номер: RU2011146120A
Принадлежит:

... 1. Соединение, характеризующееся следующей формулой I:где Z представляет собой узловую структуру, содержащую от четырех до двенадцати атомов углерода;каждая G представляет собой независимо выбранную группу (поли)глицерина;каждая (Hphob) представляет собой независимо выбранную гидрофобную функциональную группу;каждая L представляет собой независимо выбранную первичную связывающую группу;каждая L' представляет собой независимо выбранную первичную связывающую группу;каждая L'' представляет собой независимо выбранную вторичную связывающую группу;каждая (Nu) представляет собой независимо выбранную нуклеофильную группу;x принимает значения от 1 до 12;h принимает значения от 0 до 11;y принимает значения от 0 до 5;a принимает значения от 0 до 11;сумма x+h принимает значения от 4 до 12; исумма h+y принимает значения от 1 до 12,при условии, что Z является полинуклеофильным остатком, полученным из сорбитана, и либо: (a) x=2, h=2, a=0, y=0, и степень полимеризации глицерина в соединении составляет ...

Подробнее
20-04-2005 дата публикации

СПОСОБЫ ПОЛУЧЕНИЯ 3-О-ДЕЗАКТИВИРОВАННОГО 4`-МОНОФОСФОРИЛЛИПИДА А (3D-MLA)

Номер: RU2003131677A
Принадлежит:

... 1. Способ получения композиций липополисахарида (LPS), включающий: a) выращивание культуры сильно шероховатого (deep rough) мутантного бактериального штамма в среде; b) выдерживание культуры в стационарной фазе, по крайней мере, около 5 ч; c) сбор клеток из культуры; d) экстрагирование LPS из клеток. 2. Способ по п.1, в котором мутантный бактериальный штамм deep rough принадлежит к роду Salmonella. 3. Способ по п.2, в котором мутантный бактериальный штамм deep rough из рода Salmonella относится к виду Salmonella minnesota. 4. Способ по п.3, в котором мутантный бактериальный штамм deep rough из вида Salmonella minnesota представлен штаммом Salmonella minnesota R595. 5. Способ по п.1, в котором среда представляет собой М9. 6. Способ по п.1, в котором выдерживание осуществляется на протяжении от около 5 ч до около 6 ч. 7. Способ по п.1, в котором LPS может использоваться для получения 3D-MLA, содержащего, по меньшей мере, 20 мол.% группы гексаацильных вариантов. 8. Способ по п.1, дополнительно ...

Подробнее
23-08-1993 дата публикации

CПOCOБ ПOЛУЧEHИЯ AHAЛOГOB ЛИПИДA A

Номер: RU1836378C
Автор:
Принадлежит:

Подробнее
17-04-2008 дата публикации

MONO- UND DISACCHARIDDERIVATE

Номер: DE0060038248D1
Принадлежит: COVACCINE B V, COVACCINE B.V.

Подробнее
26-03-1981 дата публикации

VERFAHREN ZUR HERSTELLUNG VON SUCROGLYZERIDEN

Номер: DE0003030553A1
Принадлежит:

Подробнее
14-09-1989 дата публикации

PROCESS FOR ESTERIFICATION

Номер: DE0003664915D1
Принадлежит: NOVO INDUSTRI AS, NOVO INDUSTRI A/S

Подробнее
11-04-1974 дата публикации

Номер: DE0002041932C3
Принадлежит: TAITO CO., LTD., TOKIO

Подробнее
22-06-1995 дата публикации

Pseudoceramide, Verfahren zu ihrer Herstellung und ihre Verwendung

Номер: DE0004402929C1

The proposal is for novel pseudo-ceramides of the formula (I) in which R<1> is a linear alkyl and/or alkenyl radical with 6 to 30 carbon atoms, R<2> is hydrogen or a possibly hydroxy-substituted alkyl radical with 1 to 30 carbon atoms, R<3> is an oligo-hydroxyalkyl radical with 4 to 12 carbon atoms and 3 to 10 hydroxyl groups or a glycosyl radical, X is a linear or branched alkylene radical with 1 to 6 carbon atoms, Y is oxygen, sulphur or an NR<4> radical and R<4> is hydrogen or an alkyl radical with 1 to 30 carbon atoms. The substances are suitable as "synthetic barrier lipids" for the production of skin-care agents.

Подробнее
24-11-1977 дата публикации

FRUCTOSE-FETTSAEUREESTER UND VERFAHREN ZU IHRER HERSTELLUNG

Номер: DE0002440942B2
Автор:
Принадлежит:

Подробнее
13-05-2004 дата публикации

PHOSPHOGLYCOLIPID UND VERFAHREN ZU DESSEN VERWENDUNG

Номер: DE0069916289D1
Принадлежит: CORIXA CORP, CORIXA CORP., SEATTLE

Подробнее
04-05-2005 дата публикации

EIN VERBESSERTES VERFAHREN ZUR SYNTHESE VON SACCHAROSE-6-ESTERN

Номер: DE0060109787D1
Принадлежит: TATE & LYLE PLC, TATE & LYLE P.L.C., LONDON

Подробнее
28-12-1967 дата публикации

Verfahren zur Herstellung von oelloeslichen oberflaechenaktiven Mischestern

Номер: DE0001257130B
Автор: SCHOU HERBERT
Принадлежит: SCHOU HERBERT, HERBERT SCHOU

Подробнее
07-02-2018 дата публикации

Emulsifier surcrose stearate production plant

Номер: GB0201721988D0
Автор:
Принадлежит:

Подробнее
12-02-1986 дата публикации

MANUFACTURE OF SUGAR ESTERS

Номер: GB0002162844A
Принадлежит:

The invention relates to an improved process for the synthesis of sugar esters carried out in a substantially anhydrous system and in the presence of an organic acid chloride. Any of the known available sugars may be used and in particular hydrolyzate sugars derived from starch are effectively employed in accordance with the present invention to produce sugar esters having superior emulsifying characteristics for use as an ingredient in food products for human consumption.

Подробнее
25-07-1984 дата публикации

a,a-Trehalose-6,6'-middle chained aliphatic acid diester and a pharmaceutical agent containing the same

Номер: GB0002133399A
Принадлежит:

Disclosed herein is a novel alpha , alpha -trehalose-6,6'-middle chained aliphatic acid diester represented by the following formula (I): in which n represents an integer from 6 to 10. This compound is produced, for instance, by converting alpha , alpha -trehalose into 2,3,2',3'-tetra-o-benzyl- alpha , alpha -trehalose then reacting it with a middle chained aliphatic acid or its active derivative into a novel intermediate 2,3,2',3'-tetra-o- benzyl- alpha , alpha -trehalose-6,6'-middle chained aliphatic acid diester and further reducing de-benzylating it using a reduction catalyst. The compound according to the invention has an excellent antitumor activity, antibiotic activity and action for delayed-type hypersensitivity, and is useful for pharmaceuticals. Pharmaceutical agents containing an alpha , alpha -trehalose-6,6'-middle chained aliphatic acid diester of the formula (I) as an effective ingredient are also disclosed.

Подробнее
17-02-1982 дата публикации

Production of sucrose-fatty acid esters

Номер: GB0002081266A
Принадлежит:

Sucrose-fatty acid esters are by melting an alkali metal soap of a fatty acid free of water or other solvent, adding sucrose and a fatty acid ester to the molten soap to give a homogeneous molten mixture of these reaction components, and heating the molten mixture at a temperature from 125 DEG C to 165 DEG C under vacuum. Conventional basic transesterification catalysts and/or inert metal salts may be added to the molten mixture.

Подробнее
12-01-1983 дата публикации

Purification of sucrose esters

Номер: GB0002101122A
Принадлежит:

Sucrose ester-containing material obtained by base-catalysed transesterification of sucrose with a fatty acid ester is purified by a process comprises the steps of: (i) acidifying an aqueous dispersion of the material to between pH 4 and 7 to give an aqueous phase and an organic phase; (ii) at or above the melt temperature of the organic phase, recovering the organic phase; (iii) mixing the organic phase with ethyl acetate containing 0 to 4% water, to give at a temperature of 0 to 20 DEG C a liquid phase and a solid phase; and (iv) recovering the solid phase as a sucrose ester-rich product.

Подробнее
06-01-2010 дата публикации

Process for the production of sucrose-6-ester

Номер: GB0000920383D0
Автор:
Принадлежит:

Подробнее
09-02-2000 дата публикации

Fabric softening compounds and compositions

Номер: GB0009930105D0
Автор:
Принадлежит:

Подробнее
15-01-2008 дата публикации

AQUEOUS IMMUNOLOGICAL ADJUVANTZUSAMMENSETZUNGEN OUT MONOPHOSPHORYLLIPID A

Номер: AT0000381344T
Автор: CRANE R, CRANE, R.
Принадлежит:

Подробнее
15-01-2012 дата публикации

PRODUCTION OF CLEANED ONES POLYOLE FETTSÄUREPARTIALESTERN

Номер: AT0000540963T
Принадлежит:

Подробнее
15-11-1978 дата публикации

PROCEDURE FOR A REINGIGEN A SACCHAROSE ESTER HALTIGEN SURFACE-ACTIVE MATERIAL

Номер: AT0000286776A
Автор:
Принадлежит:

Подробнее
15-12-1994 дата публикации

PROCEDURE FOR THE SYNTHESIS OF TUBING SUGAR DERIVATIVES BY A REGIOKSELEKTIVE REACTION.

Номер: AT0000114664T
Принадлежит:

Подробнее
15-04-1998 дата публикации

LIPID A DERIVATIVES AS WELL AS THEIR USES

Номер: AT0000164517T
Принадлежит:

Подробнее
15-02-1992 дата публикации

GLUCOPYRANOSE DERIVATIVES.

Номер: AT0000072443T
Принадлежит:

Подробнее
15-10-2006 дата публикации

LIPID A AND LIPID A ABSTENTION TOPI, IN PARTICULAR COSMETIC ONES, COMPOSITION

Номер: AT0000339431T
Принадлежит:

Подробнее
10-12-1976 дата публикации

PROCEDURE FOR THE PRODUCTION OF NEW OF MIXTURES OF PARTIALESTER

Номер: AT0000333781B
Принадлежит:

Подробнее
15-08-1998 дата публикации

PROCEDURE FOR THE IMPROVEMENT OF OXIDATIVE STABILITY OF POLYOLE FATTY ACID POLYESTER

Номер: AT0000169026T
Принадлежит:

Подробнее
15-04-2002 дата публикации

GEMAHLENE MIXTURES CONTAINING POLYOLE AND PROCEDURE FOR THEIR PRODUCTION

Номер: AT0000215548T
Принадлежит:

Подробнее
03-12-1981 дата публикации

PREPARATION OF SUCROSE ESTERS

Номер: AU0005890780A
Автор: JONES H F, H.F. JONES
Принадлежит:

Подробнее
14-03-2013 дата публикации

C-glycolipids with enhanced TH-1 profile

Номер: AU2007253715B2
Принадлежит:

The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI -type immune response characterized by enhanced IL- 12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.

Подробнее
14-06-2007 дата публикации

Process for production of compound labeled with radioactive fluorine

Номер: AU2006322673A1
Принадлежит:

Подробнее
23-01-2014 дата публикации

Polyglyceryl compounds and compositions

Номер: AU2011250743B2
Принадлежит:

Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about I I and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. Also provided are polyglyceryl compounds, compositions comprising water, a surfactant, and a polyglyceryl thickener, as well as, methods of making polyglyceryl compounds and compositions of the present invention. (FIGURE 1) ...

Подробнее
03-01-1991 дата публикации

PROCESS FOR PURIFYING PRODUCTS CONTAINING ESTERS O

Номер: AU0005765690A
Принадлежит:

Подробнее
26-03-2020 дата публикации

Improved peptide pharmaceuticals for insulin resistance

Номер: AU2015266854B2
Принадлежит: AJ PARK

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

Подробнее
08-06-1989 дата публикации

METHOD OF PURIFYING CRUDE POLYOL FATTY ACID POLYESTERS

Номер: AU0002638688A
Автор: NAME NOT GIVEN
Принадлежит:

Подробнее
27-01-1989 дата публикации

PROCESS FOR THE PREPARATION OF POLYOL FATTY ACID ESTERS

Номер: AU0001916388A
Автор: NAME NOT GIVEN
Принадлежит:

Подробнее
14-09-1989 дата публикации

METHOD OF PRODUCING SUCROSE FATTY ACID ESTER GRANULES

Номер: AU0002869089A
Принадлежит:

Подробнее
26-05-2009 дата публикации

MONO- AND DISACCHARIDE DERIVATIVES

Номер: CA0002393072C
Принадлежит: PROTHERICS MOLECULAR DESIGN LIMITED

The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for.inter alia, medical, pharmaceutical, cosmetic and food applications.

Подробнее
20-11-2018 дата публикации

POLYGLYCERYL COMPOUNDS AND COMPOSITIONS

Номер: CA0002757974C

Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about 11 and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. The composition may be used as thickeners in personal care products. An examplary compound of the composition is ( see above formula) ...

Подробнее
15-05-2012 дата публикации

POLYGLYCERYL COMPOUNDS AND COMPOSITIONS

Номер: CA0002757999A1
Принадлежит:

Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about 11 and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. Also provided are polyglyceryl compounds, compositions comprising water, a surfactant, and a polyglyceryl thickener, as well as, methods of making polyglyceryl compounds and compositions of the present invention.

Подробнее
25-10-2016 дата публикации

METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS

Номер: CA0002743796C

The invention relates to methods for making deoxyribofuranose compounds such as compound (2) which are useful intermediates in the preparation of pharmaceutical compounds such as 5-amino -3-(2'-O-acetyl-3'-deoxy-.beta.3-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

Подробнее
20-05-2010 дата публикации

METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS

Номер: CA0002743796A1
Принадлежит:

The invention relates to methods for making deoxyribofuranose compounds such as compound (2) which are useful intermediates in the preparation of pharmaceutical compounds such as 5-amino-3-(2'-O-acetyl-3'-deoxy-ß-D-ribofuranosyl)-3H- thiazolo[4,5-d]pyrimidin-2-one and the like.

Подробнее
14-10-2010 дата публикации

6"-SIALYLLACTOSE SALTS AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER A-SIALYLOLIGOSACCHARIDES

Номер: CA0002757685A1
Принадлежит:

The present invention relates to a process of synthesis of a-sialyl oligosaccharides and in particular of 6'-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.

Подробнее
12-09-1989 дата публикации

DISACCHARIDE AND TRISACCHARIDE DERIVATIVES OF THE "LIPID A" TYPE

Номер: CA1259308A
Принадлежит: AKZO NV, AKZO N.V.

The present invention is dealing with certain disaccharide or trisaccharide derivatives of the lipid A type, which have interesting immuno-modulating, more particularly immuno-stimulating properties.

Подробнее
22-12-1987 дата публикации

N-GLYCOSYLATED CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR INFLUENCING THE BODY'S INHERENT DEFENCES

Номер: CA1230594A
Принадлежит: BAYER AG, BAYER AKTIENGESELLSCHAFT

N-Glycosylated carboxamide derivatives, process for their preparation and their use for influencing the body's inherent defences The invention relates to N-glycosylated carboxamide derivatives of Formula I which are useful for influencing the body's inherent defenses, e.g. for increasing immune system antibodies. Also included in the invention are compositions containing said N-glycosylated carboxamide derivative of Formula I as active ingredients and methods for the use of said compounds and compositions.

Подробнее
24-07-1979 дата публикации

SYNTHESIS OF HIGHER POLYOL FATTY ACID POLYESTERS

Номер: CA1059121A

SYNTHESIS OF HIGHER POLYOL FATTY ACID POLYESTERS Harry M. Taylor and George P. Rizzi A solvent-free transesterification comprising the steps of (1) heating a mixture of a polyol, a fatty acid lower alkyl ester, an alkali metal fatty acid soap, and a basic catalyst to form a homogenous melt; and (2) subsequently adding to the reaction product of step (1) excess fatty acid lower alkyl esters yields polyol fatty acid polyesters.

Подробнее
26-10-1993 дата публикации

PROCESS FOR SYNTHESIZING SUCROSE DERIVATIVES BY REPROCESS FOR SYNTHESIZING SUCROSE DERIVATIVES BY REGIOSELECTIVE REACTION GIOSELECTIVE REACTION

Номер: CA0001323625C
Принадлежит: NAVIA JUAN L, NAVIA, JUAN L.

Sucrose is reacted with a 1,3-di(hydrocarbyloxy)-1,1,3,3-tetra(hydrocarbyl)distannoxane to produce a 1,3-di-(6-0-sucrose)-1,1,3,3-tetra(hydrocarbyl)distannoxane, which can be acylated to produce a sucrose-6-ester.

Подробнее
13-06-1995 дата публикации

SACCHARIDE DERIVATIVES

Номер: CA0001335892C
Принадлежит: SANDOZ LTD, SANDOZ LTD.

The saccharides of formula I, I wherein R1, R2 and R3 independently are optionally substituted acyl, are novel. They possess interesting pharmacological, especially immunostimulant, antiinflammatory and antitumor properties. They may be obtained by deprotection of a corresponding compound in protected form.

Подробнее
05-12-1989 дата публикации

DERIVATIVE OF .alpha.-.alpha.TREHALOSE AND A PROCESS FOR PREPARING THE SAME

Номер: CA0001263649A1
Принадлежит:

Подробнее
05-08-1999 дата публикации

PROCESS FOR SYNTHESIS OF POLYOL FATTY ACID POLYESTERS

Номер: CA0002319276A1
Принадлежит:

A process for preparing esterified polyol fatty acid polyesters is provided, where the polyol has n hydroxyl groups. The process provides for independent control of the level of fully esterified polyols, on the one hand, and the level of n-3 and lower esters, on the other hand. The process is especially suited for preparing sucrose polyester, wherein the process provides for independent control of the level of octaesters, on the one hand, and penta and lower level esters, on the other hand. The process can be used to reduce the level of undesirable reaction byproducts, such as difatty ketone and beta ketoester.

Подробнее
24-02-2000 дата публикации

LOWER ALKYL ESTER RECYCLING SYNTHESIS

Номер: CA0002337944A1
Принадлежит:

... ▓▓▓Process for synthesizing and purifying polyol fatty acids polyesters or other ▓nondigestible fats selected from the group of esterified linked alkoxylated ▓polyols and esterified epoxide extended polyols, in which unreacted lower ▓alkyl ester is recovered from a reaction mixture and recycled for use in the ▓synthesis of the nondigestible fat. The process includes the steps of reacting ▓an excess of lower alkyl ester with polyol to esterify hydroxyl groups thereof ▓and form polyol fatty acid polyester, separating at least a portion of the ▓unreacted lower alkyl ester from the polyol fatty acid polyester, and ▓recycling the separated unreacted lower alkyl ester for further reaction with ▓polyol or partially esterified polyol. The recycled lower alkyl ester is ▓substantially free of lower alkyl ester degradation reaction products, such as ▓carbonyls and free fatty acids.▓ ...

Подробнее
30-09-1999 дата публикации

SYNTHESIS OF HIGHER POLYOL FATTY ACID POLYESTERS BY TRANSESTERIFICATION

Номер: CA0002325410A1
Принадлежит:

A process for synthesizing polyol fatty acid polyesters comprising the steps of (1) mixing ingredients comprising (a) unesterified first polyol having hydroxyl groups, (b) second polyol esterified with fatty acids, (c) basic catalyst, and (d) emulsifying agent to form a mixture of ingredients; (2) reacting the mixture of ingredients at a temperature sufficient to obtain a transesterification reaction products and by-products; and (3) removing at least a portion of the by-products from the transesterification reaction mixture; and (4) further heating the transesterification reaction products and ingredients from step (3) at a temperature and for a time sufficient to esterify at least about 50 % of the hydroxyl groups of the first polyol.

Подробнее
24-07-1979 дата публикации

SYNTHESIS OF HIGHER POLYOL FATTY ACID POLYESTERS

Номер: CA0001059121A1
Принадлежит:

Подробнее
18-01-2018 дата публикации

GLYCOLIPID COMPOSITIONS AND METHODS OF USE

Номер: CA0003030974A1
Принадлежит:

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

Подробнее
09-11-2004 дата публикации

PROCESS FOR SYNTHESIS OF POLYOL FATTY ACID POLYESTERS

Номер: CA0002319276C
Принадлежит: THE PROCTER & GAMBLE COMPANY

A process for preparing esterified polyol fatty acid polyesters is provided, where the polyol has n hydroxyl groups. The process provides for independent control of the level of fully esterified polyols, on the one hand, and the level of n-3 and lower esters, on the other hand. The process is especially suited for preparing sucrose polyester, wherein the process provides for independent control of the level of octaesters, on the one hand, and penta and lower level esters, on the other hand. The process can be used to reduce the level of undesirable reaction byproducts, such as difatty ketone and beta ketoester.

Подробнее
13-12-2012 дата публикации

Aminoglycosides: synthesis and use as antifungals

Номер: US20120316125A1
Принадлежит: Utah State University USU

The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.

Подробнее
25-04-2013 дата публикации

Compositions and methods for treating nephropathy

Номер: US20130101514A1
Автор: Daniel Joseph Cushing
Принадлежит: Complexa Inc

Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.

Подробнее
05-09-2013 дата публикации

POLYETHERESTER POLYOLS AND THE USE THEREOF FOR PRODUCING RIGID POLYURETHANE FOAMS

Номер: US20130231413A1
Принадлежит:

The invention relates to a polyetherester polyol comprising the reaction product of 1. A polyetherester polyol comprising the reaction product ofa1) 5 to 63 wt % of one or more polyols or polyamines or mixtures thereof having an average functionality of 2.5 to 8,a2) 2 to 50 wt % of one or more fatty acids, fatty acid monoesters or mixtures thereof,a3) 35 to 70 wt % of one or more alkylene oxides of 2 to 4 carbon atoms.2. The polyetherester polyol according to wherein the polyols or polyamines of component a1) are selected from the group consisting of sugars claim 1 , pentaerythritol claim 1 , sorbitol claim 1 , trimethylolpropane claim 1 , glycerol claim 1 , tolylenediamine claim 1 , ethylenediamine claim 1 , ethylene glycol claim 1 , propylene glycol and water.3. The polyetherester polyol according to wherein said component a1) comprises a mixture of glycerol and sucrose.4. The polyetherester polyol according to wherein said component a2) comprises oleic acid claim 2 , stearic acid claim 2 , palmitic acid claim 2 , linolenic acid claim 2 , their monoesters or mixtures thereof.5. The polyetherester polyol according to wherein the alkylene oxide of component a3) is propylene oxide.6. The polyetherester polyol according to wherein it has an OH number of 200 to 700 mg KOH/g.7. The polyetherester polyol according to wherein it has a functionality of 2.5 to 8.8. A process for producing rigid polyurethane foams by reaction ofA) organic or modified organic polyisocyanates or mixtures thereof,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'B) one or more polyetherester polyols according to ,'}C) optionally further polyester polyols,D) optionally polyetherol polyols,E) one or more blowing agents,F) catalysts, andG) optionally further auxiliaries and/or additives.9. A rigid polyurethane foam obtainable by the process according to .10. A polyol mixture comprising as components{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'B) one or more polyetherester polyols according ...

Подробнее
17-10-2013 дата публикации

TRISACCHARIDE DERIVATES, AND THEIR USE AS ADJUVANTS

Номер: US20130273082A1
Принадлежит: IMMUNOVO B.V.

The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions. 138-. (canceled)39. An adjuvant composition comprising:a trisaccharide derivate as the adjuvant, which derivate comprises a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups; andat least one of a pharmaceutical acceptable excipient and diluent.40. The adjuvant according to claim 39 , wherein the substituted trisaccharide core is derived from raffinose claim 39 , melezitose claim 39 , maltotriose claim 39 , nigerotriose claim 39 , maltotriulose or kestose claim 39 , preferably raffinose claim 39 , melezitose or maltotriose claim 39 , most preferably raffinose or maltotriose.41. The adjuvant according to claim 39 , wherein the substituted trisaccharide core comprises one or two sulphate ester or phosphate ester groups as anionic groups.42. The adjuvant according to claim 41 , wherein the anionic group is a sulphate ester.43. The adjuvant according to claim 39 , wherein the fatty acid ester group is an ester of a straight claim 39 , branched claim 39 , saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms.44. The adjuvant according to claim 39 , wherein the fatty acid ester is the ester of lauric acid claim 39 , myristic acid claim 39 , palmitic acid claim 39 , stearic acid or arachidic acid.45. The adjuvant according to claim 39 , wherein the fatty acid ester groups of the substituted trisaccharide core are all identical.46. The adjuvant according ...

Подробнее
17-10-2013 дата публикации

DISACCHARIDE SYNTHETIC LIPID COMPOUNDS AND USES THEREOF

Номер: US20130273149A1
Принадлежит:

Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources. 3. The essentially pure compound of claim 2 , wherein AA claim 2 , and Aare each independently Cto Cunsubstituted alkyl and Aand Aare each independently are Cto Cunsubstituted alkyl.6. The essentially pure compound of claim 5 , wherein AA claim 5 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.9. The essentially pure compound of claim 8 , wherein AA claim 8 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.11. The essentially pure compound of claim 1 , wherein the compounds is at least 95% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.12. The essentially pure compound of claim 5 , wherein the compounds is at least 99% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.15. The pharmaceutical composition of claim 14 , wherein AA claim 14 , and Aare each independently Cto Cunsubstituted alkyl and Aand Aare each independently are Cto Cunsubstituted alkyl.18. The pharmaceutical composition of claim 17 , wherein AA claim 17 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.21. The pharmaceutical composition of claim 20 , wherein AA claim 20 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.23. The pharmaceutical composition of claim 13 , wherein the compounds is at least 95% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.24. The pharmaceutical composition of claim 13 , wherein the compounds is at least 99% pure with respect to the synthetic ...

Подробнее
07-01-2021 дата публикации

TRITERPENE SAPONIN ANALOGUES

Номер: US20210002316A1
Принадлежит:

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases. 3. The pharmaceutical composition according to claim 2 , wherein the antigen is associated with a bacteria or virus.4pertussisBorreliaB. burgdorferi, B. garinii, B. afzelliB. japonica.. The pharmaceutical composition according to claim 3 , wherein the antigen is associated with a bacterial or virus causing a disease selected from the group consisting of Hepatitis B claim 3 , pneumococcus claim 3 , diphtheria claim 3 , tetanus claim 3 , claim 3 , or Lyme disease including the closely related spirochetes of the genus such as claim 3 , claim 3 , and5. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with Hepatitis B virus.6bacterium.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with pneumococcus7Corynebacterium diphtheria bacterium.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with8Clostridium tetani bacterium.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with9Bordetella pertussis bacterium.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with10bacteriumBorreliaB. burgdorferi, B. garinii, B. afzelliB. japonica.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with a causing Lyme disease or a spirochete of the genus selected from the group consisting of claim 4 , and12. The method according to claim 11 , wherein the antigen is an antigen associated with a bacteria or a virus.13pertussisBorreliaB. burgdorferi, B. ...

Подробнее
10-01-2019 дата публикации

TRITERPENE SAPONIN VARIANTS, METHODS OF SYNTHESIS AND USE THEREOF

Номер: US20190010181A1
Принадлежит:

A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants. 6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein G is hydrogen.13. A pharmaceutical composition claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the compound of or a pharmaceutically acceptable salt thereof;'}an immunologically effective amount of an antigen; anda pharmaceutically acceptable excipient.14. A method for immunizing a subject claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00013', 'claim 13'}, 'administering to the subject an effective amount of the pharmaceutical composition of .'}15. A method for treating a disorder in a subject claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'administering to the subject an effective amount of the pharmaceutical composition of ,'}wherein the disorder is cancer, an infectious disease or a neurodegenerative disorder. The present application claims priority under 35 U.S. C. § 119(e) to U.S. provisional application U.S. 62/268,837, filed Dec. 17, 2015, the contents of which are incorporated herein by reference.This invention was made with government support under R01 AI085622, R01 GM058833 and P30 CA008748 awarded by National Institutes of Health. The government has certain rights in the invention.The present invention generally relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. More specifically, the invention relates to saponin variants with central glycosidic linkage modifications that exhibit distinct conformations and adjuvant activities.Most of the immunological adjuvants are emulsions that stimulate an immune response, which have shown valuable potentials in the development of vaccines against toxins and viruses such as diphtheria-tetanus-pertussis, ...

Подробнее
30-01-2020 дата публикации

Mobile Rhamnolipid Contamination Response

Номер: US20200031690A1
Автор: DeSanto Keith
Принадлежит:

Our mobile rhamnolipid production vehicles can convert pollutants obtained from contaminated sites into rhamnolipid. Then, our mobile rhamnolipid application units can alter, treat and remove pollutants from soil and water. Our new rhamnolipid application can use various sources for power. All these new components combined are cost efficient. Moreover, the mobile rhamnolipid contamination response vehicles are easy to mobilize and can be deployed and up and running with a short amount of time and effort. 1. An application where , rhamnolipid production tanks for producing rhamnolipid are fixed on a vehicle that is mobile.2. An application as in where the mobile vehicle can be a boat claim 1 , ship claim 1 , train claim 1 , jet claim 1 , airplane or land roaming vehicle.3. An application as in and where each rhamnolipid production tank is short and stacked on top of one another.4. An application as in claim 1 , and where the rhamnolipid production tanks are stacked on top of one another and placed side by side and be made of plastic claim 1 , metal or a combination of both.5. An application in where the rhamnolipid production tanks are connected to other similar mobile vehicle units.6. An application as in through where the rhamnolipid production tanks are connected to each other by metal pipe and or plastic pipe and or electrical power sources.7. An application as in through where the rhamnolipid production tanks are powered by solar power claim 1 , natural gas claim 1 , power from running water claim 1 , wind turbines or electricity.8. An application as in through where the rhamnolipid production tanks are connected and operated wirelessly.9. An application as in through where the rhamnolipid production tanks are monitored and or managed by drones from land claim 1 , from water or from the air.10. An application as in through where the rhamnolipid production tanks are connected wirelessly by drones for communication purposes.11. An application using through to ...

Подробнее
01-05-2014 дата публикации

ANTITUMOR AGENT

Номер: US20140121175A1
Принадлежит: KINKI UNIVERSITY

The invention is intended to provide an excellent antitumor agent. An antitumor agent contains a glycolipid glycoside compound represented by Formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: 2. The antitumor agent according to claim 1 ,{'sup': 1', '4, 'wherein in Formula (1), Rto Rare the same as or different from each other and are a lower to higher alkanoyl group or a hydrogen atom, and A is a sugar alcohol residue or a polyol residue.'}3. The antitumor agent according to claim 1 ,{'sup': 1', '4, 'wherein in Formula (1), Rto R, are the same as or different from each other and are an alkanoyl group having 3 to 16 carbon atoms or a hydrogen atom, and A is a sugar alcohol residue having 3 to 7 carbon atoms or a polyol residue having 2 to 3 carbon atoms.'}5. The antitumor agent according to claim 4 ,{'sub': 2', 'k', '2, 'wherein in Formula (1a), f, h, m and n represent an integer of 2 to 8, and —CH(CHOH)CHOH is a sugar alcohol residue having 4 to 7 carbon atoms or a glycerin residue.'} This application is a national stage application under 35 U.S.C. §371 of PCT International Application No. PCT/JP2012/063686 which has an International filing date of May 2012. PCT/JP2012/063868 claims priority under 35 U.S.C. §119 to Japanese Application No. 2011-119797 filed on 27 May 2011 and to Japanese Application No. 2012-097198 filed on 20 Apr. 2012. The contents of each application recited above are incorporated herein by reference in their entirety.The present invention relates to an antitumor agent containing a novel glycolipid glycoside compound or a pharmacologically acceptable salt thereof as an active ingredient.The invention relates to an antitumor agent containing a novel compound discovered by a new screening method that the inventors of the invention have developed, as an active ingredient. The compound, which has a pentitol and a hexitol chain as an aglycone, and in which all hydroxyl groups of a mannose ring which is a mother ...

Подробнее
04-03-2021 дата публикации

GLYCOSIDE COMPOUND OF FATTY ACIDS, COMPOSITION COMPRISING IT, PROCESS FOR ITS OBTENTION AND METHODS TO APPLY IT ON PLANTS OR FRUITS OR BOTH AT THE SAME TIME

Номер: US20210059250A1
Принадлежит:

A glycoside compound of fatty acids that includes the general formula: GalNAc-GalNAc-Glc-O—R, where GalNAc is α- or β-D-N-acetylgalactosamine, Glc-O—R is a molecule of α- or β-D-glucose esterified to a monounsaturated fatty acid (R), where R is selected from 12:1(n) and where n is an integer between 2 and 11; 11:1(n) and where n is an integer between 2 and 10; 10:1(n), and where n is an integer between 2 and 9; 9:1(n), and where n is an integer between 2 and 8; 8:1(n), and where n is an integer between 2 and 8; 7:1(n) and where n is an integer between 2 and 7; and 6:1(n), and where n is an integer between 2 and 6. The compound has activity against plant pathogens, and induces the defense, and promotes the growth, of plants. 1. A glycoside compound of fatty acids , comprising a general formula:{'br': None, 'GalNAc-GalNAc-Glc-O—R,'}where GalNAc is α- or β-D-N-acetylgalactosamine, Glc-O—R is a molecule of α- or β-D-glucose esterified to a monounsaturated fatty acid (R), where R is selected from 12:1(n) and where n is an integer between 2 and 11; 11:1(n) and where n is an integer between 2 and 10;10:1(n), and where n is an integer between 2 and 9; 9:1(n), and where n is an integer between 2 and 8; 8:1(n), and where n is an integer between 2 and 8; 7:1(n) and where n is an integer between 2 and 7; and 6:1(n), and where n is an integer between 2 and 6.2. A composition for the promotion of plant growth , comprising a fatty acid glycoside having the general formula:{'br': None, 'GalNAc-GalNAc-Glc-O—R,'}where GalNAc is α- or β-D-N-acetylgalactosamine, Glc-O—R is a molecule of α- or β-D-glucose esterified to a monounsaturated fatty acid (R), where R is selected from 12:1(n) and where n is an integer between 2 and 11; 11:1(n) and where n is an integer between 2 and 10; 10:1(n), and where n is an integer between 2 and 9; 9:1(n), and where n is an integer between 2 and 8; 8:1(n), and where n is an integer between 2 and 8; 7:1(n) and where n is an integer between 2 and 7; and 6:1 ...

Подробнее
02-03-2017 дата публикации

Trisaccharide Derivates, and Their Use as Adjuvants

Номер: US20170057987A1
Принадлежит:

The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions. 110-. (canceled)11. A trisaccharide derivate comprising a substituted trisaccharide core , which trisaccharide core is fully substituted with fatty acid ester groups , and optionally one or more anionic groups as an adjuvant.12. The trisaccharide derivate according to claim 11 , wherein the substituted trisaccharide core is derived from raffinose claim 11 , melezitose claim 11 , maltotriose claim 11 , nigerotriose claim 11 , maltotriulose or kestose.13. The trisaccharide derivate according to claim 11 , wherein the substituted trisaccharide core comprises one or two sulphate ester or phosphate ester groups as anionic groups.14. The trisaccharide derivate according to claim 11 , wherein the anionic group is a sulphate ester.15. The trisaccharide derivate according to claim 11 , wherein the fatty acid ester group is an ester of a straight claim 11 , branched claim 11 , saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms.16. The trisaccharide derivate according to claim 11 , wherein the fatty acid ester is the ester of lauric acid claim 11 , myristic acid claim 11 , palmitic acid claim 11 , stearic acid or arachidic acid.17. The trisaccharide derivate according to claim 11 , wherein the fatty acid ester groups of the substituted trisaccharide core are all identical.18. The trisaccharide derivate according to claim 11 , wherein the substituted trisaccharide core is derived from raffinose claim 11 , melezitose or maltotriose and wherein the ...

Подробнее
29-03-2018 дата публикации

Dextrin fatty acid ester and cosmetic

Номер: US20180085299A1
Принадлежит: Chiba Flour Milling Co Ltd

A dextrin fatty acid ester is provided in which the dextrin has an average degree of glycopolymerization of 3 or more and 100 or less. The fatty acid comprises one or more linear saturated fatty acids having 14 or more and 18 or less carbon atoms, and one or more branched saturated fatty acids having 14 or more and 18 or less carbon atoms. The molar fraction of the linear saturated fatty acid in the fatty acid is 0.75 or more and 0.95 or less. The average degree of substitution of the fatty acid per glucose unit is 1.5 or more and 2.0 or less.

Подробнее
12-05-2022 дата публикации

Liquid dispersions for acyl halides

Номер: US20220145541A1
Принадлежит: Greentech Global Pte Ltd

The present disclosure describes acyl halide liquid dispersions and tunable methods of treating cellulosic materials with compositions that provide increased hydrophobicity and/or lipophobicity to such materials without sacrificing the biodegradability thereof. The methods as disclosed provide for reacting acyl halides with and binding of saccharide fatty acid esters on cellulosic materials, including that the disclosure provides products made by such methods. The materials thus treated display higher hydrophobicity, lipophobicity, barrier function, and mechanical properties, and may be used in any application where such features are desired.

Подробнее
06-04-2017 дата публикации

Improved peptide pharmaceuticals for insulin resistance

Номер: US20170096468A1
Автор: John J. Nestor
Принадлежит: Mederis Diabetes LLC, Spitfire Pharma Inc

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

Подробнее
23-04-2015 дата публикации

Disaccharide Synthetic Lipid Compounds and Uses Thereof

Номер: US20150110854A1
Принадлежит:

Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources. 3. The essentially pure compound of claim 2 , wherein AA claim 2 , and Aare each independently Cto Cunsubstituted alkyl and Aand Aare each independently are Cto Cunsubstituted alkyl.6. The essentially pure compound of claim 5 , wherein AA claim 5 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.9. The essentially pure compound of claim 8 , wherein A claim 8 , A claim 8 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.11. The essentially pure compound of claim 1 , wherein the compounds is at least 95% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.12. The essentially pure compound of claim 5 , wherein the compounds is at least 99% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.15. The pharmaceutical composition of claim 14 , wherein A claim 14 , A claim 14 , and Aare each independently Cto Cunsubstituted alkyl and Aand Aare each independently are Cto Cunsubstituted alkyl.18. The pharmaceutical composition of claim 17 , wherein AA claim 17 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.21. The pharmaceutical composition of claim 20 , wherein A claim 20 , A claim 20 , and Aare each independently Cto Cunsubstituted alkyl and Ais a Cto Cunsubstituted alkyl.23. The pharmaceutical composition of claim 13 , wherein the compounds is at least 95% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.24. The pharmaceutical composition of claim 13 , wherein the compounds is at least 99% ...

Подробнее
02-04-2020 дата публикации

Agricultural Coating Containing Sugar Ester and Methods

Номер: US20200102457A1
Принадлежит: Renuvix LLC

The invention is a coating for agricultural products, which includes at least 10% of renewably sourced and biodegradable sugar esters. The invention is also a method of making a coated agricultural product, including the steps of providing a coating composition comprising at least 10% of a renewably sourced and biodegradable sugar ester, heating the coating composition to a temperature to reduce its viscosity to below about 100 cP, adding the coating composition to an agricultural product to form a mixture, and cooling the mixture to produce a coated agricultural product. The invention is also a method of reducing dust released from an agricultural product that includes the step of providing a coating composition comprising at least 10% of a renewable sourced and biodegradable sugar ester. Enough of the coating composition is added to the agricultural product to reduce the amount of dust released from the agricultural product by at least half. Finally, the invention is also a method of reducing caking in a granular agricultural product. 1. A coating for agricultural products , the coating comprising at least 10% of renewably sourced and biodegradable sugar esters.2. The invention of wherein the agricultural product is a granular or prilled fertilizer.3. The invention of wherein the agricultural product is seed.4. The invention of wherein the agricultural product is a granular or prilled pesticide.5. The invention of wherein the sugar ester is sucrose ester.6. The invention of wherein the sucrose ester is sucrose octaester.7. The invention of wherein the ester portion of the sucrose ester compound is derived from soybean oil claim 1 , high oleic soybean oil claim 1 , hydrogenated soybean oil claim 1 , high oleic soybean oil claim 1 , sunflower oil claim 1 , safflower oil claim 1 , canola oil claim 1 , corn oil claim 1 , tung oil claim 1 , palm oil claim 1 , cottonseed oil claim 1 , linseed oil claim 1 , rapeseed oil claim 1 , camelina oil claim 1 , jatropha oil claim ...

Подробнее
26-04-2018 дата публикации

BIOCONJUGATE MOLECULES WITH BIOLOGICAL AND TECHNO-FUNCTIONAL ACTIVITY, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF

Номер: US20180110869A1
Принадлежит:

The present invention regards the synthesis of bioconjugated molecules, formed between two or more of the following functional groups: sugars, prebiotics, oligosaccharides, polysaccharides, triglycerides, fatty acids, fatty acids esters, anti-inflammatories; with its production process by biocatalyzed synthesis with hydrolases such as esterases, proteases, lipases or cutinases, and its purification with several methods that include washing and drying. In addition, its applications in foods, pharmaceuticals and cosmetics, such as: prebiotic nutraceutical, anti-inflammatory, antitumoral, intestinal vector, techno-functional ingredient for food applications (emulsifier, fat substitute) and cosmetic emollient; which are possible since these are non toxic molecules according to the Ames tests. 1. (canceled)2. (canceled)3. (canceled)4. A process for the production of bioconjugated molecules with biological and techno-functional activities with a weight ratio of 1:1 to 1:10 of sugars , oligosaccharides or branched polysaccharides: carboxylic acid or its derivative , the process including the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a. producing a reaction by mixing on a hermetically closed recipient with agitation at 100-1000 r.p.m. and incubation at 40-80° C., two substrates according to in a proportion of 1:1 to 1:10 w/w, in presence of an enzyme in a proportion of 1:1 to 1:10 w/w to the acylating agent; with or without solvent that if it is added is in a ratio of 1:2 to 1:100 w/v;'}b. filtering with Whatman filters numbers 1,3,4, or similar, or centrifuge for separation of the organic solvent and the immobilized enzyme;c. recovering the bioconjugates from the “organic phase” by solvent evaporation at reduced pressure (vacuum) in a rotary evaporator, heating at a temperature where the solvent boils depending on the vacuum used, or by heating at a temperature above the solvent boiling point; and{'b': '4', 'd. recovering the bioconjugates from the “solid ...

Подробнее
30-04-2015 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR AND NEUROLOGICAL DISEASES

Номер: US20150119344A1
Автор: Kandula Mahesh
Принадлежит:

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III and methods for the treatment of cardiovascular and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, postprandial hyperglycemia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, inflammation, Crohn's disease, inflammatory bowel disease and obesity. 4. A Pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.5. A Pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.6. A Pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.7. The pharmaceutical composition of claim 4 , which is formulated to treat cardiovascular and neurological diseases the underlying etiology with an effective amount administering the patient in need by oral administration claim 4 , delayed release or sustained release claim 4 , transmucosal claim 4 , syrup claim 4 , topical claim 4 , parenteral administration claim 4 , injection claim 4 , subdermal claim 4 , oral solution claim 4 , rectal administration claim 4 , buccal administration or transdermal administration.8. The pharmaceutical composition of claim 5 , which is formulated to treat cardiovascular and ...

Подробнее
18-04-2019 дата публикации

Composition, Crocins Active Site, and Uses Thereof

Номер: US20190112326A1
Принадлежит:

A composition, and a crocins active site extracted from Ellis, mainly comprising the following ingredients: crocetin di-β-D-gentiobioside, crocetin-β-D-glucopyranosyl-β-D-gentiobioside, crocetin di-β-D-glucopyranoside, 13Z-crocetin di-β-D-gentiobioside, neocrocin B, crocetin mono-β-D-gentiobioside, 13Z-crocetin-8-O-β-D-gentiobioside, 13Z-crocetin-8′-O-β-D-gentiobioside, and crocetin mono-β-D-glucopyranoside. Pharmacological experiment results show that the crocins active site can effectively improve learning and memory injuries in mice induced by scopolamine and amyloid β protein. 117-. (canceled)19. The composition according to claim 18 , which further comprises crocetin mono-β-D-gentiobioside.20. The composition according to claim 18 , which further comprises 13Z-crocetin di-β-D-gentiobioside.21. The composition according to claim 18 , which further comprises crocetin-β-D-glucopyranosyl-β-D-gentiobioside.22. The composition according to claim 18 , which further comprises crocetin-β-D-glucopyranosyl-β-D-gentiobioside claim 18 , crocetin di-β-D-glucopyranoside claim 18 , 13Z-crocetin di-β-D-gentiobioside claim 18 , crocetin mono-β-D-gentiobioside claim 18 , 13Z-crocetin-8-O-β-D-gentiobioside claim 18 , 13Z-crocetin-8′-O-β-D-gentiobioside claim 18 , and crocetin mono-β-D-glucopyranoside.24. A crocins active site claim 18 , comprising the composition according to .25Gardenia jasminoides. The crocins active site according to claim 24 , wherein the crocins active site is extracted from Ellis.26. The crocins active site according to claim 24 , wherein a UPLC characteristic chromatogram of the crocins active site comprises 9 chromatographic peaks claim 24 , a retention time of crocetin mono-β-D-gentiobioside is set as 1 claim 24 , and values of relative retention time are obtained for the various chromatographic peaks respectively claim 24 , the retention time of crocetin di-β-D-gentiobioside is 0.38±0.02 claim 24 , the retention time of crocetin-β-D-glucopyranosyl-β-D- ...

Подробнее
17-07-2014 дата публикации

Polyols, preparation and use thereof

Номер: US20140200327A1
Принадлежит: BASF SE

The present invention relates to polyols and the preparation and use thereof.

Подробнее
10-05-2018 дата публикации

OIL-BASED INK COMPOSITION FOR WRITING INSTRUMENTS, AND WRITING INSTRUMENT, MARKING PEN AND BALLPOINT PEN COMPRISING THE SAME

Номер: US20180127609A1
Автор: NAKAMURA Hisashi
Принадлежит: KABUSHIKI KAISHA PILOT CORPORATION

An oil-based ink composition for a writing instrument, comprising a dye, an organic solvent and a phenolic compound of the following general formula (1): 2. The ink composition according to claim 1 , wherein the content of the phenolic compound is 0.5 to 10% by mass based on the total mass of the ink composition.3. The ink composition according to claim 1 , wherein the dye is a solvent dye.4. The ink composition according to claim 1 , wherein a vapor pressure of the organic solvent at 20° C. is 10 to 50 mmHg.5. The ink composition according to claim 1 , wherein a boiling point of the organic solvent is 160 to 250° C.6. The ink composition according to claim 1 , further comprising a resin.7. The ink composition according to claim 6 , wherein the resin is a ketone resin.8. The ink composition according to claim 1 , further comprising a sucrose fatty acid ester.9. A writing instrument claim 1 , comprising the oil-based ink composition for a writing instrument according to .10. The writing instrument according to claim 9 , selected from the group consisting of marking pens and ballpoint pens. The present invention relates to an oil-based ink composition for a writing instrument, and a writing instrument, a marking pen and a ballpoint pen comprising the oil-based ink composition. More particularly, the present invention relates to an oil-based ink composition for a writing instrument which can form handwriting having excellent water resistance, and a writing instrument, a marking pen and a ballpoint pen comprising the oil-based ink composition.A dye is conventionally contained as a coloring agent into an oil-based ink composition because of excellent color development, but an oil-based ink composition including a dye is prone to lower water resistance so that bleeding of handwriting in which the ink composition bleeds from handwriting to spread to the circumference occurs by adhesion of water. Taking this problem into consideration, though a metallized dye is included ...

Подробнее
23-04-2020 дата публикации

METHODS OF TREATING SEPSIS USING ANTI-SEPSIS LIPID A (ASLA) BASED THERAPEUTICS

Номер: US20200121705A1
Принадлежит: University of Maryland, Baltimore

The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein Rand Rmay be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, Rmay be OH or a mono-, di- or poly-saccharide, R, R, Rand Rmay be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R, R, Rand Rmay be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof. 2. The method of claim 1 , wherein the sepsis is attributed to an infection in the subject by a Gram-negative microorganism.4. The method of claim 1 , wherein the sepsis is associated with a condition selected from the group consisting of systemic inflammatory response syndrome (SIRS) claim 1 , and multiple organ dysfunction syndrome (MODS).5. claim 1 , The method of claim 1 , wherein the compound is administered by a method selected from the group consisting of intraperitoneal administration claim 1 , intraarterial administration claim 1 , and intravenous administration.6. The method of claim 1 , wherein the compound is administered at a dose of between about 2 mg/kilogram to about 30 mg/kilogram of the subject.28. A method of screening a molecule for anti-sepsis activity claim 1 , comprisingi) genetically engineering a Gram-negative microorganism to produce a lipid A mimetic;ii) isolating the lipid A mimetic from the microorganism; andiii) assaying the lipid A mimetic for anti-sepsis activity. This application claims the benefit of U.S. Provisional Appl. No. 62/403,950, filed Oct. 4, 2016, the contents of which are hereby incorporated by reference in their entirety.This invention was made with government support under Grant Number AI123820 awarded by the National Institutes of Health. The government has certain rights in the invention.The invention relates to infectious disease, in particular to methods of treating and preventing sepsis.Sepsis, ...

Подробнее
23-04-2020 дата публикации

MODIFIED LIPOPOLYSACCHARIDE GLYCOFORM AND METHOD OF USE

Номер: US20200121786A1
Принадлежит:

The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described. 1. A vaccine adjuvant comprising at least one of a lipopolysaccharide isolated from a mutant O-antigen ligase or lipopolysaccharide derivative isolated from the mutant O-antigen ligase , the mutant O-antigen ligase comprising either an isolated protein that has the amino acid sequence SEQ ID NO: 1 , or an isolated protein having at least 90% sequence identity to SEQ ID NO: 2 and having an amino acid substitution of phenylalanine to serine at the phenylalanine homologous to position 332 of SEQ ID NO: 2 ,wherein the isolated protein has at least one of O-antigen ligase activity or the activity to ligate lipid A to disaccharide pentapeptide (DPP).2. A vaccine adjuvant comprising a lipopolysaccharide derivative molecule prepared by the process comprising the steps of:{'i': 'E. coli', 'providing an strain adapted to express a LPS derivative molecule having reduced endotoxicity compared to a LPS molecule that the LPS derivative molecule is derived from;'}{'i': 'E. coli', 'claim-text': a mutant O-antigen ligase comprising an isolated protein that has the amino acid sequence SEQ ID NO: 1, and', 'a mutant O-antigen ligase comprising an isolated protein having at least 90% sequence identity to SEQ ID NO: 2 and having an amino acid substitution of phenylalanine to serine at the phenylalanine homologous to position 332 of SEQ ID NO: 2, wherein the protein has at least one of O-antigen ligase activity or the activity to ligate lipid A to disaccharide pentapeptide (DPP); and, 'modifying the strain by creating a mutant O-antigen ligase selected from the group consisting of{'i': 'E. coli', 'allowing the modified strain to grow under conditions to produce ...

Подробнее
03-06-2021 дата публикации

MONOESTER SUGAR DERIVATIVES AS FLAVOR MODIFIERS

Номер: US20210161189A1
Принадлежит: FIRMENICH SA

Compositions containing monoester derivatives of the primary alcohol residue of a sugar are generally disclosed herein, as well as their use as sweetness enhancers, bitterness maskers, sourness maskers, or astringency reducers, to improve the taste profile of a flavored article. 1. A flavored article comprising a flavor-enhancing compound , wherein the flavor-enhancing compound is a monoester derivative of a primary alcohol residue of a sugar compound , which comprises a sugar moiety and an acid moiety.2. The flavored article of claim 1 , wherein the sugar moiety of the flavor-enhancing compound is a monosaccharide moiety.3. The flavored article of claim 2 , wherein the sugar moiety of the flavor-enhancing compound is a hexose moiety.4. The flavored article of claim 3 , wherein the sugar moiety of the flavor-enhancing compound is an allose moiety claim 3 , an altrose moiety claim 3 , a glucose moiety claim 3 , a mannose moiety claim 3 , a gulose moiety claim 3 , an idose moiety claim 3 , a galactose moiety claim 3 , a talose moiety claim 3 , a psicose moiety claim 3 , a fructose moiety claim 3 , a sorbose moiety claim 3 , or a tagatose moiety.5. The flavored article of claim 4 , wherein the sugar moiety of the flavor-enhancing compound is a glucose moiety.6. The flavored article of any one of to claim 4 , wherein the acid moiety of the flavor-enhancing compound is a Cfatty acid moiety.7. The flavored article of claim 6 , wherein the acid moiety of the flavor-enhancing compound is a hexanoate moiety claim 6 , an octanoate moiety claim 6 , a decanoate moiety claim 6 , a 9-decenoate moiety claim 6 , a 10-undecenoate moiety claim 6 , a dodecanoate moiety claim 6 , a 9-dodecenoate moiety claim 6 , a tetradecanoate moiety claim 6 , a hexadecanoate moiety claim 6 , an octadecanoate moiety claim 6 , an oleate moiety claim 6 , a linoleate moiety claim 6 , a linolenate moiety claim 6 , an eicosapentaenoate moiet claim 6 , or a docosahexaenoate moiety.8. The flavored article ...

Подробнее
19-05-2016 дата публикации

Disaccharide Synthetic Lipid Compounds and Uses Thereof

Номер: US20160136271A1
Принадлежит:

Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources. 2. The essentially pure compound of claim 1 , wherein AA claim 1 , and Aare each independently Cto Cunsubstituted alkyl.3. The essentially pure compound of claim 1 , wherein Aand Aare each independently are Cto Cunsubstituted alkyl.4. The essentially pure compound of claim 1 , wherein AA claim 1 , and Aare each independently Cto Cunsubstituted alkyl and Aand Aare each independently are Cto Cunsubstituted alkyl.5. The essentially pure compound of claim 1 , wherein AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each Cor AA claim 1 , and Aare each Cand Aand Aare each C.6. The essentially pure compound of claim 1 , wherein AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each C; AA claim 1 , and Aare each Cand Aand Aare each Cor AA claim 1 , and Aare each Cand Aand Aare each C.7. The essentially pure compound of claim 1 , wherein the compounds is at least 95% pure with respect to the synthetic disaccharide lipid compounds as measured on a weight basis.9. The pharmaceutical composition of claim 8 , wherein AA claim 8 , and Aare each independently Cto Cunsubstituted alkyl.10. The pharmaceutical composition of claim 8 , wherein Aand Aare each independently are Cto Cunsubstituted alkyl.11. The pharmaceutical composition of claim 8 , wherein AA claim 8 , and ...

Подробнее
02-06-2016 дата публикации

BETA-GLYCOLIPIDS FOR USE AS ADJUVANTS

Номер: US20160151483A1
Принадлежит:

The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycol-lipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy. 2. The vaccine adjuvant of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aor Rand Rare claim 1 , independently of each other claim 1 , saturated or monounsaturated linear C-Calkyl.3. The vaccine adjuvant of claim 2 , wherein claim 2 , in the beta-glycolipid derivative claim 2 , Aand Aor Rand Rare claim 2 , independently of each other claim 2 , moieties of lauric acid claim 2 , myristic acid claim 2 , palmitic acid claim 2 , stearic acid claim 2 , arachidic acid claim 2 , behenic acid or lignoceric acid.4. The vaccine adjuvant of claim 2 , wherein claim 2 , in the beta-glycolipid derivative claim 2 , Aand Aor Rand Rare claim 2 , independently of each other claim 2 , saturated or monounsaturated linear C-Calkyl.5. The vaccine adjuvant of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aare acyl —(CO)Rand acyl —(CO)Rrespectively claim 1 , where Rand Rare claim 1 , independently of each other claim 1 , a moiety of pentadecanoic acid claim 1 , palmitic acid claim 1 , heptadecanoic acid claim 1 , or stearic acid.6. The vaccine adjuvant of claim 1 , wherein the beta-glycolipid derivative of formula (I) is in the form of a salt thereof claim 1 , wherein X is a —SO claim 1 , —OSO claim 1 , —OPO claim 1 , —PO claim 1 , alkali or alkaline-earth metal group.7. The vaccine adjuvant of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , X is —SOH claim 1 , —SONa claim 1 , or —SOK.8. The vaccine adjuvant of claim 1 , wherein the beta-glycolipid ...

Подробнее
28-08-2014 дата публикации

Methods for the Production of 3-O-Deactivated-4'-Monophosphoryl Lipid A (3D-MLA)

Номер: US20140243513A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS S.A.

Herein is disclosed a method for producing lipopolysaccharide (LPS), comprising: (a) growing a culture of a deep rough mutant bacterial strain in a medium; (b) maintaining the culture in stationary phase for at least about 5 hr; (c) harvesting, cells from the culture; and (d) extracting LPS from the cells. The method allows for the production of an LPS which can be used to produce a 3-O-deacylated monophosphoryl lipid A (3D-MLA) having at least about 20 mol % of the hexaacyl congener group. 1. A method of extracting lipopolysaccharide (LPS) from a culture of deep rough mutant bacterial strain cells , comprising:a. Extracting the cells with a solution consisting essentially of at least 75 wt % of an aliphatic alcohol having from 1 to 4 carbon atoms and the balance water, thereby producing cells with reduced phospholipid content;b. Extracting the cells with reduced phospholipid content with a solution comprising chloroform and methanol, thereby yielding a solution of LPS in chloroform and methanol,wherein the extracting with aliphatic alcohol is performed at a temperature between 35° C. and 65° C.2SalmonellaEscherichia.. The method of claim 1 , wherein the deep rough mutant bacterial strain is of the genera or3SalmonellaSalmonella minnesota.. The method of claim 2 , wherein the deep rough mutant bacterial strain of genus is of species4Salmonella minnesotaSalmonella minnesota. The method of claim 3 , wherein the deep rough mutant bacterial strain of species is strain R595.5EscherichiaEschenchia coli.. The method of claim 2 , wherein the deep rough mutant bacterial strain of genus is of species6Escherichia coilEscherichia coil. The method of claim 5 , wherein the deep rough mutant bacterial strain of species is of strain D31m4.7. The method of claim 1 , wherein the aliphatic alcohol has from 2 to 4 carbon atoms.8. The method of claim 7 , wherein the aliphatic alcohol is ethanol.9. The method of claim 1 , wherein the solution comprising aliphatic alcohol comprises ...

Подробнее
04-09-2014 дата публикации

TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND

Номер: US20140248317A1
Принадлежит: GLYTECH, INC.

A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R—CHR— (wherein Rand Reach represents a C-Calkyl group or the like) or the like; and n and n′ each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils. 2. The method according to claim 1 , wherein X represents R—CHR— and X′ represents R—CHR′—.3. The method according to claim 2 , wherein R claim 2 , R′ claim 2 , Rand R′ independently represent a linear C-Calkyl group claim 2 , and n and n′ independently represent 0 or 1.4. The method according to claim 2 , wherein R claim 2 , R′ claim 2 , Rand R′ independently represent a linear C-Calkyl group claim 2 , and n and n′ independently represent 0.5. The method according to claim 2 , wherein R claim 2 , R′ claim 2 , Rand R′ independently represent a linear C-Calkyl group claim 2 , and n and n′ independently represent 1.6. The method according to claim 1 , wherein Ris identical to R′ claim 1 , Ris identical to R′ claim 1 , and n is identical to n′.7. The method according to claim 1 , wherein the compound is selected from the group consisting of:6,6′-bis-O-(2-octyldecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-nonylundecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-decyldodecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-undecyltridecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-dodecyltetradecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-tridecylpentadecanoyl)-α,α′-trehalose,6,6′-bis-O-(2-pentadecylheptadecanoyl)-α,α′-trehalose, and6,6′-bis-O-(2-hexadecyloctadecanoyl)-α,α′-trehalose.8. The method according to claim 1 , wherein the compound is selected from the group consisting of:6,6′-bis-O-(3-nonyldodecanoyl)-α,α′-trehalose,6,6′-bis-O-(3-decyltridecanoyl)-α,α′-trehalose,6,6′-bis-O-(3-undecyltetradecanoyl)-α,α′-trehalose,6,6′-bis-O-(3-dodecylpentadecanoyl)-α,α′-trehalose,6,6′-bis-O-(3-tridecylhexadecanoyl)-α,α′-trehalose, and6,6′- ...

Подробнее
06-06-2019 дата публикации

Fungal Trisaccharide Ester Compounds and Use Thereof in Preparing Agents for Preventing and Controlling Plant Fungal Diseases

Номер: US20190166835A1
Принадлежит: South China Botanical Garden of CAS

Fungal trisaccharide ester compounds and agents containing the fungal trisaccharide ester compounds as active ingredients for preventing and controlling plant fungal diseases. A Pezicula sp. strain SC1337 was isolated from endophytes of a branch of bald cypress. The strain SC1337 is capable of producing five compounds exhibiting significant inhibitory activities against twelve common plant pathogenic fungi and preservative effect on fruits. Thus, the strain SC1337 can be used to prepare the five compounds exhibiting significant inhibitory activities against twelve common plant pathogenic fungi and preservative effect on fruits and used for preventing and controlling plant pathogenic fungi and fruit preservation.

Подробнее
22-06-2017 дата публикации

NOVEL MATERIALS DERIVED FROM FERMENTATION-PRODUCED RHAMNOLIPIDS AND METHODS OF PRODUCTION

Номер: US20170175151A1
Автор: Ju Lu-Kwang, Miao Shida
Принадлежит:

A method of preparing a product derived from a rhamnolipid includes the steps of: providing a rhamnolipid, combining the rhamnolipid with a reagent, allowing the rhamnolipid and reagent to react to form a product derived from the rhamnolipid, and collecting the product derived from the rhamnolipid. An exemplary product is dimeric β-hydroxy fatty acid. 2. The compound of claim 1 , where Cand Care each alkyl chains having seven carbon atoms.3. The compound of claim 2 , where Xand Xare each hydroxyl groups.4. A polymer formed from a plurality of the compounds of .6. The compound of claim 5 , where Cand Care each alkyl chains having seven carbon atoms.9. A polymer formed from a plurality of the compounds of .10. A polymer formed from a plurality of the compounds of .11. A method of preparing a product derived from a rhamnolipid comprising the steps of:providing a rhamnolipid,combining the rhamnolipid with a reagent,allowing the rhamnolipid and reagent to react to form a product derived from the rhamnolipid, andcollecting the product derived from the rhamnolipid.12. The method of claim 11 , wherein the reagent is an acid claim 11 , wherein the reaction mixture further comprises an alcohol claim 11 , wherein the rhamnolipid is a rhamnolipid mixture comprising both mono-rhamnolipids and di-rhamnolipids claim 11 , and wherein the product is dimeric β-hydroxy fatty acid.13. The method of claim 12 , wherein the rhamnolipid is a mono-rhamnolipid.14. The method of claim 12 , further comprising the steps of:adding a catalyst to the collected product, andheating the collected product after the adding step,whereby the steps of adding and heating polymerize the dimeric β-hydroxy fatty acid.15. The method of claim 11 , wherein the reagent is a base in solution with an alcohol claim 11 , wherein the rhamnolipid comprises two β-hydroxy fatty acids claim 11 , and wherein the product is a rhamnolipid comprising only one β-hydroxy fatty acid.16. The method of claim 11 , wherein the ...

Подробнее
04-06-2020 дата публикации

DEXTRIN FATTY ACID ESTER AND COSMETIC

Номер: US20200170917A1
Принадлежит:

A dextrin fatty acid ester is provided in which the dextrin has an average degree of glycopolymerization of 3 or more and 100 or less. The fatty acid comprises one or more linear saturated fatty acids having 14 or more and 18 or less carbon atoms, and one or more branched saturated fatty acids having 14 or more and 18 or less carbon atoms. The molar fraction of the linear saturated fatty acid in the fatty acid is 0.75 or more and 0.95 or less. The average degree of substitution of the fatty acid per glucose unit is 1.5 or more and 2.0 or less. 1. A cosmetic comprising:an oil; anda dextrin fatty acid ester whereinthe dextrin has an average degree of glycopolymerization of 3 or more and 100 or less,the fatty acid comprises one or more linear saturated fatty acids having 14 or more and 18 or less carbon atoms and one or more branched saturated fatty acids having 14 or more and 18 or less carbon atoms,the molar fraction of the linear saturated fatty acid in the fatty acid is 0.8 or more and 0.9 or less, andthe average degree of substitution of the fatty acid per glucose unit is 1.61 or more and 1.80 or less.2. The cosmetic according to claim 1 , wherein the oil comprises a volatile hydrocarbon oil.3. The cosmetic according to claim 1 , wherein the content of the dextrin fatty acid ester in the cosmetic is 3% by weight or more and 20% by weight or less.4. The cosmetic according to claim 1 , wherein the cosmetic is gelled.5. The cosmetic according to claim 1 , wherein the average degree of glycopolymerization of the dextrin is 3 or more and 50 or less.6. The cosmetic according to claim 1 , wherein the average degree of glycopolymerization of the dextrin is 3 or more and 20 or less.7. The cosmetic according to claim 1 , wherein the average degree of substitution of the fatty acid per glucose unit is 1.65 or more and 1.80 or less.8. The cosmetic according to claim 1 , wherein the linear saturated fatty acid is palmitic acid claim 1 , and the branched saturated fatty acid is ...

Подробнее
13-06-2019 дата публикации

Crocins Compounds and Uses Thereof

Номер: US20190177354A1
Принадлежит: Jinan University

Provided are a series of crocins compounds and related pharmacological applications thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Ellis, as a raw material and separating same by means of various methods. The compounds playing a role in preventing oxidative injury caused by hydrogen peroxide (HO) and excitatory amino acid injury caused by L-glutamic acid are screened out by in-vitro cell experiments. The results show that the crocins compounds have good effect in preventing cell injury caused by HOand L-glutamic acid. The compounds have good effect in preventing and treating Alzheimer's disease due to the fact that significant rise of oxidative stress and excitatory amino acid is a key factor for nerve injury in Alzheimer's disease, and have broad development and application prospect. 121-. (canceled)23. The compound according to claim 22 , wherein the configuration of the double bound is the trans E configuration claim 22 , Rrepresents glucosyl group claim 22 , and Rrepresents quinic acid group.25. The compound according to claim 22 , wherein the configuration of the double bound is the cis Z configuration claim 22 , Rrepresents H claim 22 , a glucosyl group claim 22 , or a quinic acid group claim 22 , and Rrepresents H claim 22 , a glucosyl group claim 22 , or a quinic acid group.27. The compound according to claim 22 , wherein the configuration of the double bond the trans E configuration claim 22 , Rrepresents a glucosyl group claim 22 , and Rrepresents a glucosyl group or H.29. The compound according to claim 22 , wherein the configuration of the double bond is the trans E configuration claim 22 , Rrepresents a glucosyl group claim 22 , and Rrepresents CHCH.31. The compound according to claim 22 , wherein the configuration of the double bond is the trans E configuration claim 22 , Rrepresents a glucosyl group or a xylosyl group claim 22 , and Rrepresents H.33. A method ...

Подробнее
29-06-2017 дата публикации

METHOD FOR PRODUCING SUCROSE FATTY ACID ESTER

Номер: US20170183371A1
Принадлежит: Microwave Chemical Co., Ltd.

The present invention provides a method for producing a sucrose fatty acid ester having high monoester selectivity, the method for producing a sucrose fatty acid ester comprising a step of preparing an aqueous solution containing sucrose and a basic catalyst; and a step of producing a sucrose fatty acid ester, by mixing the aqueous solution obtained in the aforementioned step, a fatty acid alkali metal salt and a melted fatty acid ester, and heating the mixture with stirring under reduced pressure, wherein the step of producing a sucrose fatty acid ester has an earlier step of removing water from the mixture, and a subsequent step of performing transesterification after the earlier step, and, in the subsequent step, heating is performed through microwave irradiation such that the temperature of the mixture is below the sucrose decomposition temperature. 1. A method for producing a sucrose fatty acid ester , comprising:a step of preparing an aqueous solution containing sucrose and a basic catalyst; and wherein the step of producing a sucrose fatty acid ester has an earlier step of removing water from the mixture, and a subsequent step of performing transesterification after the earlier step, and', 'in the subsequent step, heating is performed through microwave irradiation such that the temperature of the mixture is below a decomposition temperature of the sucrose., 'a step of producing a sucrose fatty acid ester, by mixing the aqueous solution obtained in the aforementioned step, a fatty acid alkali metal salt, and a fatty acid ester, and heating the mixture with stirring under reduced pressure,'}2. The method for producing a sucrose fatty acid ester according to claim 1 , wherein a sucrose fatty acid ester with a monoester weight proportion of 60% by weight or more is produced.3. The method for producing a sucrose fatty acid ester according to claim 1 , wherein the fatty acid ester is a fatty acid ester whose constituent fatty acid includes at least one selected ...

Подробнее
20-06-2019 дата публикации

PROCESS FOR PRODUCING SUGAR FATTY ACID ESTER USING ANION EXCHANGER AS CATALYST

Номер: US20190185504A1
Принадлежит: TOHOKU UNIVERSITY

An object of the present invention is to solve the various problems with the conventional process for producing a sugar fatty acid ester, such as a sucrose fatty acid ester (FASuc), and to provide a process which has advantages such as no production of a soap by-product and ease of separation between the catalyst and the product and also enables efficient synthesis by a simple operation under mild conditions in a flow system, and to provide a composition including the sugar fatty acid ester. The present invention is directed to a process for producing a sugar fatty acid ester by a transesterification reaction of a fatty acid ester and a saccharide using an anion exchanger as a catalyst, and to a composition including such a sugar fatty acid ester. 1. A process for producing a sugar fatty acid ester , comprising performing a transesterification reaction of a fatty acid ester and a saccharide using an anion exchanger as a catalyst.2. The process according to claim 1 , wherein the saccharide is virtually pre-adsorbed on the anion exchanger.3. The process according to claim 2 , which comprises the steps of: adsorbing the saccharide on the anion exchanger and then synthesizing the sugar fatty acid ester using the anion exchanger on which the saccharide has been adsorbed in the adsorbing step.4. The process according to claim 3 , wherein the adsorbing step comprises feeding a reaction solution containing the saccharide to the anion exchanger to adsorb the saccharide on the anion exchanger.5. The process according to claim 3 , wherein the synthesizing step comprises feeding a reaction solution containing the fatty acid ester to the anion exchanger on which the saccharide has been adsorbed in the adsorbing step to synthesize the sugar fatty acid ester.6. The process according to claim 5 , wherein the reaction solution containing the fatty acid ester further contains the saccharide.7. The process according to claim 6 , wherein the reaction solution used in the synthesizing ...

Подробнее
13-07-2017 дата публикации

DEFINED ENZYMATIC SYNTHESIS OF LIPID A ANALOGS

Номер: US20170198003A1
Автор: Khosla Chaitan, Xiao Xirui
Принадлежит:

Provided herein include methods and compositions for synthesis of Lipid IVand derivatives thereof, using a defined set of pathway enzyme, which may be isolated and used to reconstitute all or part of the pathway in a cell-free reaction. 2. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.3. The composition of claim 1 , wherein the compound has a structure of any one of Formula 6a claim 1 , 6b claim 1 , 6c claim 1 , 6d or 6e as shown in .4. A method of synthesizing a compound of claim 1 , the method comprising:combining in a reaction mixture one or more of the following sets of enzymes:Module A: Acetyl-CoA carboxylases;Module B: chain initiation enzymes of fatty acid synthases;Module C: chain elongation enzymes of fatty acid synthases;Module D: Lipid A biosynthetic enzymes; in the presence of Acetyl-CoA or an analog thereof including valeryl-CoA, UDP-GlcNAc, and cofactors and buffers required for synthesis.5. A method of synthesizing a compound of claim 1 , the method comprising:combining in a reaction mixture the following sets of enzymes:Module A, comprised of AccC, AccA, AccD, and holo-AccB; Module B comprised of FabH, FabD, FabG, FabA or FabZ, Fabl, and holo-ACP; Module C, comprised of FabB or FabF, FabD, FabG, FabA or FabZ, and Fabl; and Module D, comprised of LpxA, LpxC, LpxD, LpxH, LpxB, and LpxK, in the presence of Acetyl-CoA or an analog thereof including valeryl-CoA, UDP-GlcNAc, and cofactors and buffers required for synthesis.6. A method of synthesizing a compound of claim 1 , the method comprising:combining in a reaction mixture the following sets of enzymes:Module B comprised of FabH, FabD, FabG, FabA or FabZ, Fabl, and holo-ACP; Module C, comprised of FabB or FabF, FabD, FabG, FabA or FabZ, and Fabl; and Module D, comprised of LpxA, LpxC, LpxD, LpxH, LpxB, and LpxK, in the presence of malonyl-CoA, Acetyl-CoA or an analog thereof including valeryl-CoA, UDP-GlcNAc, and cofactors and buffers required for synthesis.7. ...

Подробнее
30-10-2014 дата публикации

CHEMICALLY MODIFIED SOPHOROLIPIDS AND USES THEREOF

Номер: US20140322755A1
Автор: Huang Tom Tao
Принадлежит:

The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi. 2. The compound of claim 1 , wherein Ris an aliphatic moiety selected from the group consisting of unsubstituted C1-C24 alkyl claim 1 , substituted C1-C24 alkyl claim 1 , unsubstituted C2-C24 alkenyl claim 1 , substituted C2-C24 alkenyl claim 1 , unsubstituted C2-C24 alkynyl claim 1 , and substituted C2-C24 alkynyl.3. The compound of claim 1 , wherein Ris an aliphatic moiety selected from the group consisting of unsubstituted C1-C24 alkyl claim 1 , C1-C24 alkyl substituted with hydroxyl claim 1 , unsubstituted C2-C24 alkenyl claim 1 , C2-C24 alkenyl substituted with hydroxyl claim 1 , unsubstituted C2-C24 alkynyl claim 1 , and C2-C24 alkynyl substituted with hydroxyl.5. The compound of claim 4 , wherein Ris an aliphatic moiety selected from the group consisting of unsubstituted C1-C24 alkylene claim 4 , unsubstituted C2-C24 alkenylene claim 4 , and unsubstituted C3-C24 alkynylene.7. The compound of any one of to claim 4 , wherein the compound has an inductive effect for protein production in a fermentation host of at least two times greater than a natural sophorolipid mixture.8. The compound of claim 7 , wherein the protein is cellulase.9Candida. The compound of claim 7 , wherein the natural sophorolipid mixture is produced by a host.10. The compound of any one of to claim 7 , wherein the compound has an inductive effect for protein production in a fermentation host of at least five times greater than sophorose ...

Подробнее
24-08-2017 дата публикации

MODIFIED LIPOPOLYSACCHARIDE GLYCOFORM AND METHOD OF USE

Номер: US20170239350A1
Принадлежит: THE TRUSTEES OF PRINCETON UNIVERSITY

The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described. 1. A vaccine adjuvant comprising at least one of a lipopolysaccharide isolated from a mutant O-antigen ligase or lipopolysaccharide derivative isolated from the mutant O-antigen ligase , the mutant O-antigen ligase selected from the group consisting of:a mutant O-antigen ligase comprising an isolated protein that has the amino acid sequence SEQ ID NO: 1, anda mutant O-antigen ligase comprising an isolated protein having at least 90% sequence identity to SEQ ID NO: 2 and having an amino acid substitution of phenylalanine to serine at the phenylalanine homologous to position 332 of SEQ ID NO: 2, wherein the protein has at least one of O-antigen ligase activity or the activity to ligate lipid A to disaccharide pentapeptide (DPP).2. A lipopolysaccharide glycoform modified with peptidoglycan cell wall fragments.3. The lipopolysaccharide glycoform of claim 2 , wherein the lipopolysaccharide glycoform is adapted to display antibiotic-specific binding sites at a cell surface.4. The lipopolysaccharide glycoform of claim 3 , wherein the antibiotic is vancomycin.5. The lipopolysaccharide glycoform of claim 2 , wherein the lipopolysaccharide glycoform is adapted to activate at least one receptor within a human body.6. The lipopolysaccharide glycoform of claim 5 , wherein the at least one receptor is a TRL4 receptor.7. The lipopolysaccharide glycoform of claim 5 , wherein the at least one receptor is a MD2 receptor.8. The lipopolysaccharide glycoform of claim 5 , wherein the at least one receptor is a NOD1 receptor.9. The lipopolysaccharide glycoform of claim 5 , wherein the at least one receptor is a NOD2 receptor.10. The lipopolysaccharide glycoform ...

Подробнее
30-07-2020 дата публикации

TRITERPENE SAPONIN ANALOGUES

Номер: US20200239509A1
Принадлежит:

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases. 3. The pharmaceutical composition according to claim 2 , wherein the antigen is associated with a bacteria or virus.4BorreliaB. burgdorferi, B. garinii, B. afzelliB. japonica.. The pharmaceutical composition according to claim 3 , wherein the antigen is associated with a bacterial or virus causing a disease selected from the group consisting of Hepatitis B claim 3 , pneumococcus claim 3 , diphtheria claim 3 , tetanus claim 3 , pertussis claim 3 , or Lyme disease including the closely related spirochetes of the genus such as claim 3 , claim 3 , and5. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with Hepatitis B virus.6. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with pneumococcus bacterium.7Corynebacterium diphtheria. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with bacterium.8Clostridium tetani. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with bacterium.9Bordetella pertussis. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with bacterium.10BorreliaB. burgdorferi, B. garinii, B. afzelliB. japonica.. The pharmaceutical composition according to claim 4 , wherein the antigen is an antigen associated with a bacterium causing Lyme disease or a spirochete of the genus selected from the group consisting of claim 4 , and12. The method according to claim 11 , wherein the antigen is an antigen associated with a bacteria or a virus.13BorreliaB. burgdorferi, B. garinii, B. ...

Подробнее
07-10-2021 дата публикации

N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM

Номер: US20210308160A1
Принадлежит: Innovet Italia S.R.L.

The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin.

Подробнее
14-10-2021 дата публикации

METHOD FOR PRODUCING SUGAR FATTY ACID ESTER BY TRANSESTERIFICATION REACTION

Номер: US20210317154A1
Принадлежит: TOHOKU UNIVERSITY

The invention provides a method for producing a sugar fatty acid ester characterized in that a fatty acid ester and a saccharide are allowed to react and transesterified using a weakly basic ion exchanger having a pKof 3 to 7 as a catalyst. 1. A method for producing a sugar fatty acid ester , characterized in that a fatty acid ester and a saccharide are subjected to a transesterification reaction using a weakly basic solid catalyst.2. The method for producing a sugar fatty acid ester according to claim 1 , wherein the weakly basic solid catalyst is a weakly basic anion exchanger.3. The method for a sugar fatty acid ester according to claim 2 , wherein the weakly basic anion exchanger has a pKof 3 to 7.4. The method for producing a sugar fatty acid ester according to claim 2 , wherein the weakly basic anion exchanger is a porous-type weakly basic anion exchange resin.5. The method for producing a sugar fatty acid ester according to claim 1 , comprising a step of adsorbing a saccharide onto a weakly basic solid catalyst (adsorption step) and a step of subjecting the saccharide and a fatty acid ester to a transesterification reaction to synthesize a sugar fatty acid ester (synthesis step).6. The method for producing a sugar fatty acid ester according to claim 5 , wherein the adsorption step is a step in which a solution containing a saccharide is supplied to a weakly basic solid catalyst claim 5 , thereby adsorbing the saccharide onto the weakly basic solid catalyst.7. The method for producing a sugar fatty acid ester according to claim 5 , wherein the synthesis step is a step in which a reaction liquid containing a fatty acid ester is supplied to the weakly basic solid catalyst having the saccharide adsorbed thereon in the adsorption step claim 5 , thereby synthesizing a sugar fatty acid ester.8. The method for producing a sugar fatty acid ester according to claim 7 , wherein the reaction liquid containing a fatty acid ester contains a saccharide.8. The method for ...

Подробнее
28-09-2017 дата публикации

FATTY ACID POLYESTER DERIVATIVES OF POLYGLYCOSIDES

Номер: US20170275415A1
Принадлежит:

Fatty acid polyester derivatives of polyglycosides formed from a polyol having between 2 and 10 hydroxy functions, the 2 hydroxy functions or at least 2 of these hydroxy functions being bound to the anomeric carbon of a reducing carbohydrate that is identical or different for each hydroxy group and selected from the monosaccharides and disaccharides, in which at least one of the other hydroxy groups of the monosaccharide or the disaccharide is esterified by a lipid derivative bearing at least one double bond optionally originating from a vegetable or animal oil, from a mixture of vegetable or animal oils, the double bond or the at least one of the double bonds of the lipid derivative being functionalized by a group selected from the epoxy, amine, alcohol and acid groups, and use thereof in particular in reaction formulations for the production of polymer materials. 1. Fatty acid polyester derivatives of polyglycosides comprising: a polyol comprising between 2 and 10 hydroxy functions , the 2 hydroxy functions or at least 2 of these hydroxy functions being bound to the anomeric carbon of a reducing carbohydrate that is identical or different for each hydroxy group and selected from the monosaccharides and disaccharides , in which at least one of the other hydroxy groups of said monosaccharide or of said disaccharide is esterified by a lipid derivative bearing at least one double bond optionally originating from a vegetable or animal oil of from a mixture of vegetable or animal oils , the double bond or the at least one of the double bonds of said lipid derivative being functionalized by a group selected from the epoxy , amine , alcohol and acid groups.3. The derivatives according to claim 1 , characterized in that X is a chemical structure bearing hydroxy groups of a polyol selected from glycerol claim 1 , xylitol claim 1 , phloroglucinol claim 1 , erythritol claim 1 , pentaerythritol claim 1 , dipentaerythritol claim 1 , arabitol claim 1 , ribitol claim 1 , sorbitol ...

Подробнее
12-09-2019 дата публикации

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Номер: US20190275146A1
Принадлежит: Genfit SA

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Подробнее
12-09-2019 дата публикации

BIOCONJUGATE MOLECULES WITH BIOLOGICAL AND TECHNO-FUNCTIONAL ACTIVITY, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF

Номер: US20190275163A1
Принадлежит:

The present invention regards the synthesis of bioconjugated molecules, formed between two or more of the following functional groups: sugars, prebiotics, oligosaccharides, polysaccharides, triglycerides, fatty acids, fatty acids esters, anti-inflammatories; with its production process by biocatalyzed synthesis with hydrolases such as esterases, proteases, lipases or cutinases, and its purification with several methods that include washing and drying. In addition, its applications in foods, pharmaceuticals and cosmetics, such as: prebiotic nutraceutical, anti-inflammatory, antitumoral, intestinal vector, techno-functional ingredient for food applications (emulsifier, fat substitute) and cosmetic emollient; which are possible since these are non toxic molecules according to the Ames tests. 1. Bioconjugated molecules with biological activity comprising:an oligosaccharides or a polysaccharide of fructooligosaccharides (FOS), the oligosaccharides and the polysaccharide of fructooligosaccharides (FOS) are both branched with β(2→1) and β(2→6) links; andan acylating agent selected from the group including: free fatty acids; fatty acid esters; saturated or unsaturated oils with carboxylic acids; or a mixture of oil esters, in a weight proportion of 1:1 to 1:10;wherein the oligosaccharides or polysaccharides are covalently bonded with the acylating agent producing the bioconjugates;wherein the biological activity includes nutraceutical, prebiotic, anti-inflammatory, cosmetic emollient, antitumoral, or intestinal vector.2. The bioconjugated molecules with biological and techno functional activities according to claim 1 , wherein the oligosaccharide or polysaccharide of the fructooligosaccharides branched with β(2→1) and β(2→6) links are selected from:crude agave fructans without having minerals or colors;purified oligosaccharides with short degree of polymerization (DP<10) or long degree of polymerization (DP>10); orsynthetic branched oligosaccharides with short degree of ...

Подробнее
16-11-2017 дата публикации

Sucrose ester based cationic gene vector and preparation method thereof

Номер: US20170326255A1
Принадлежит: DALIAN NATIONALITIES UNIVERSITY

The invention provides a class of sucrose ester based cationic lipids and preparation method thereof. The vector prepared using the cationic lipid can be used to deliver nucleic acid. The sucrose ester based cationic lipid is prepared by using a chemical synthesis method in the invention, wherein the synthesis method is simple, and has a relatively high product yield. A composition, including suspension, emulsion, micelle and liposome and the like, can be prepared by mixing the sucrose ester based cationic lipid compound of the invention with a co-lipid. Sucrose ester based cationic lipid complex can be prepared by using the said composition and nucleic acid, which has advantages such as simple preparation, low toxicity and high transfection efficiency, and is a novel and highly efficient gene vector.

Подробнее
23-11-2017 дата публикации

CONCENTRATED, LOW-VISCOSITY RHAMNOLIPID COMPOSITIONS

Номер: US20170335238A1
Принадлежит:

A rhamnolipid composition including 30% by weight to 70% by weight, of at least one rhamnolipid and 30% by weight to 70% by weight of water, where the percentages by weight refer to the total composition, wherein the pH of the composition at 25° C. is from 5.5 to 7.0. In addition to the foregoing rhamnolipid composition, also set forth is a method to make a solution of rhamnolipids; and a salt of at least one rhamnolipid. 1. A composition comprising30% by weight to 70% by weight, of at least one rhamnolipid and 30% by weight to 70% by weight, by weight, of water,where the percentages by weight refer to the total composition, wherein the pH of the composition at 25° C. is from 5.5 to 7.0.2. The composition according to claim 1 , wherein the total dry mass comprises 40% by weight to 98% by weight of rhamnolipids claim 1 , where the percentages by weight refer to the total dry mass.3. The composition according to claim 1 , wherein the cations of the rhamnolipid salts present are selected from the group comprising consisting of claim 1 , Li claim 1 , Na claim 1 , K claim 1 , Mg claim 1 , Ca claim 1 , Al claim 1 , NH claim 1 , primary ammonium ions claim 1 , secondary ammonium ions claim 1 , tertiary ammonium ions or quaternary ammonium ions.4. The composition according to claim 1 , wherein said composition comprises 50% by weight to 99% by weight of rhamnolipid anions claim 1 , where % by weight refers to all anions except OH present in the composition.5. The composition according to claim 1 , wherein said composition comprises 51% by weight to 95% by weight of diRL-C10C10 claim 1 ,where the percentages by weight refer to the sum total of all rhamnolipids present.6. The composition according to claim 1 , wherein said composition comprises 0.5% by weight to 9% by weight of monoRL-C10C10 claim 1 ,where the percentages by weight refer to the sum total of all rhamnolipids present.7. The composition according to claim 1 , wherein the weight ratio of all di-rhamnolipids ...

Подробнее
24-10-2019 дата публикации

SACCHARIDE FATTY ACID ESTER INORGANIC PARTICLE COMBINATIONS

Номер: US20190323177A1
Принадлежит: SM TECHNOLOGY HOLDINGS LLC

The present disclosure describes methods of treating cellulosic materials with compositions that allow greater retention of inorganic particles on cellulosic substrates. The methods as disclosed provide combining saccharide fatty acid esters (SFAE) with such inorganic particles and applying such combinations on cellulosic materials to eliminate or reduce the use of retention aids or binders for filler in the paper making process. Compositions comprising such combinations of SFAE and inorganic particles are also disclosed. 1. A composition comprising one or more saccharide fatty acid esters (SFAE) and inorganic particles , wherein said SFAE is present at a sufficient concentration to cause the inorganic particles to adhere to a cellulose based substrate , and wherein said substrate containing said composition exhibits greater water resistance and/or grease resistance compared to a substrate containing said composition comprising said inorganic particles or one or more SFAE alone.2. The composition of claim 1 , wherein the SFAE comprises all unsaturated fatty acids claim 1 , all saturated fatty acids or a mixture of saturated and unsaturated fatty acids claim 1 , and optionally claim 1 , further comprises one or more binders selected from PvOH or starch.3. The composition of claim 1 , wherein the SFAE is a mixture of two or more different SFAEs claim 1 , and wherein said two or more different SFAEs comprise all saturated fatty acids.4. The composition of claim 1 , wherein said inorganic particles are selected from the group consisting of clay claim 1 , ground calcium carbonate claim 1 , precipitated calcium carbonate claim 1 , talc claim 1 , titanium dioxide and combinations thereof claim 1 , and wherein said inorganic particles comprise at least 1% of the composition on a dry basis (db).5. The composition of claim 1 , wherein said SFAE contains at least one saccharide and at least one aliphatic group comprising 8 to 30 carbons.6. The composition of claim 4 , wherein ...

Подробнее
07-12-2017 дата публикации

Disaccharide synthetic lipid compounds and uses thereof

Номер: US20170349618A1
Принадлежит: AC IMMUNE SA, Avanti Polar Lipids Inc

Essentially pure compounds of the formulas (I) to (V) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.

Подробнее
06-12-2018 дата публикации

USE AND PREPARATION OF GLYCOLIPIDS AS ADJUVANTS IN VACCINES

Номер: US20180344843A1
Принадлежит:

The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. 2. The method of claim 1 , wherein said antigen-presenting cells are dendritic cells.3. The method of claim 1 , wherein the vaccine adjuvant composition is co-administered with an antigen against which the subject in need thereof has to be immunized.4. The method of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aor Rand Rare claim 1 , independently of each other claim 1 , saturated or monounsaturated linear C-Calkyl.5. The method of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aor Rand Rare claim 1 , independently of each other claim 1 , moieties of lauric acid claim 1 , myristic acid claim 1 , palmitic acid claim 1 , stearic acid claim 1 , arachidic acid claim 1 , behenic acid or lignoceric acid.6. The method of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aor Rand Rare claim 1 , independently of each other claim 1 , saturated or monounsaturated linear C-Calkyl.7. The method of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , Aand Aare acyl —(CO)Rand acyl —(CO)Rrespectively claim 1 , where Rand Rare claim 1 , independently of each other claim 1 , a moiety of pentadecanoic acid claim 1 , palmitic acid claim 1 , heptadecanoic acid claim 1 , or stearic acid.8. The method of claim 1 , wherein the beta-glycolipid derivative of formula (I) is in the form of a salt thereof claim 1 , wherein X is a —SO claim 1 , —OSO claim 1 , —OPO claim 1 , —PO claim 1 , alkali or alkaline-earth metal group.9. The method of claim 1 , wherein claim 1 , in the beta-glycolipid derivative claim 1 , X is —SOH claim 1 , —SONa claim 1 , or —SOK.10. The method of claim 1 , wherein the beta-glycolipid derivative of formula (I) is in the form of a complex thereof with aluminium ...

Подробнее
10-12-2020 дата публикации

USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS

Номер: US20200384105A1
Принадлежит:

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease. 2. The method of wherein the compound is of general formula (I) in which:X1 represents a halogen, a R1, or a G1-R1 group;A represents a CH═CH group;X2 represents a G2-R2 group;G1 and G2, identical or different, represent an atom of oxygen or sulfur;R1 represents an alkyl or cycloalkyl group having from one to seven carbon atoms, in particular, the alkyl or cycloalkyl group being substituted or not by one or more halogen atoms;R2 represents an alkyl group substituted by a —COOR3 group, wherein R3 represents a hydrogen atom or an alkyl group having from one to four carbon atoms;R4 and R5 represent an alkyl group having from one to four carbon atoms.3. The method of wherein the compound is of general formula (I) in which:X1 represents a R1 or G1-R1 group;A represents a CH2-CH2 group;X2 represents a G2-R2 group;G1 represents an atom of oxygen or sulfur and G2 represents an atom of oxygen;R1 represents an alkyl or cycloalkyl group having from one to seven carbon atoms;R2 represents an alkyl group substituted by at least a —COOR3 group, wherein R3 represents a hydrogen atom or an alkyl group having from one to four carbon atoms;R4 and R5 represent an alkyl group having from one to four carbon atoms.4. The method of wherein the compound is of general formula (I) in which:X1 represents a halogen atom or a R1 or G1-R1 group;A represents a CH2-CH2 group;X2 represents a G2-R2 group;G1 represents an atom of oxygen or sulfur ...

Подробнее
04-01-1990 дата публикации

Modified lipopolysaccharides

Номер: GB2220211A
Принадлежит: Ribi Immunochem Research Inc

Подробнее
04-12-2003 дата публикации

Synthesis of polyol medium fatty acid polyesters

Номер: WO2002060975A8
Принадлежит: Procter & Gamble

Processes for the preparation of polyol fatty acid polyesters comprise heating a mixture of polyol, fatty acid ester, emulsifying agent and catalyst. In one embodiment, the fatty acid chains of the fatty acid ester have from about 6 to about 14 total carbon atoms and the emulsifying agent comprises a fatty acid soap having fatty acid chains of from about 16 to about 22 total carbon atoms.

Подробнее
23-08-2000 дата публикации

Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use

Номер: EP0729473B1
Принадлежит: DEUTSCHE OM ARZNEIMITTEL GmbH, OM PHARMA SA

The invention relates to β(1→6) glucosamine disaccharides having general formula (I) to a method for preparing these disaccharides, comprising the steps of: i) providing a starting material comprising lipid A moiety of lipopolysaccharide-comprising microorganisms; and ii) subjecting the starting material to an alkaline treatment such that lipid A moiety is O-deacylated at the 3-position and at the 3'-position, to pharmaceutical compositions comprising as an active ingredient these disaccharides, and to these disaccharides for use as an immunomodulating agent, anti-tumor agent, and vaccine component.

Подробнее
11-03-1992 дата публикации

一种制备神经节苷脂相关化合物的方法

Номер: CN1015805B
Принадлежит: KANTO ISHI PHARMACEUTICAL CO Ltd

本发明提供了下式表示的神经节苷酯相关化合物及其制备方法, [式中R 1 表示氢原子或SiR 3 R 4 R 5 (其中R 3 和R 4 分别表示甲基或苯基,R 5 表示叔丁基或二甲基苯基甲基),R 2 表示氢原子,三苯甲基,或式(II) (式中M表示碱金属原子)]这些神经节苷酯相关化合物可用于早期癌症的标志,也可用于癌症的免疫疗法。

Подробнее
07-07-2022 дата публикации

Mono-tin organic compound, preparation method therefor and use thereof

Номер: WO2022141457A1
Принадлежит: 安徽金禾实业股份有限公司

The present application provides a mono-tin organic compound which is used for synthesizing sucrose-6-carboxylate. The compound is a compound represented by formula (1) below. R1, R2 and R3 each independently represent C1-C8 linear or branched saturated alkyl, C2-C8 linear or branched unsaturated alkyl, C3-C8 substituted or unsubstituted saturated cycloalkyl, C3-C8 substituted or unsubstituted unsaturated cycloalkyl or C6-C12 aryl or substituted aryl, and R4 represents C1-C6 linear or branched saturated alkyl or C6-C12 aryl or substituted aryl. The mono-tin organic compound of the present application enables accurate metering and feeding in the process of synthesizing sucrose-6-carboxylate, improves the catalyst recovery rate and reduces the occurrence of a subsequent chlorination side reaction at the same time, and has faster reaction, lower energy consumption and a higher yield per unit volume.

Подробнее
15-10-1996 дата публикации

Process for producing sucrose fatty acid ester

Номер: US5565557A
Принадлежит: Mitsubishi Chemical Corp

A process for producing a sucrose fatty acid ester wherein the sucrose fatty acid ester is recovered from a reaction mixture prepared by reacting sucrose with a fatty acid alkyl ester in the presence of an alkali catalyst by using dimethyl sulfoxide as a reaction solvent, the process comprising: (i) subjecting the reaction mixture to a first liquid-liquid extraction by using a hardly water-miscible organic solvent, which is selected from an alcohol having at least 4 carbon atoms and a ketone having at least 4 carbon atoms, and water as extractants, with regulating the pH value of an aqueous phase to 3 to 7.5, to thereby extract dimethyl sulfoxide in the reaction mixture into the aqueous phase, and the sucrose fatty acid ester into an organic solvent phase; (ii) subjecting an organic solvent solution containing the sucrose fatty acid ester thus obtained as the organic solvent phase in the first liquid-liquid extraction to a second liquid-liquid extraction by a continuous counter-current system using water, to thereby extract dimethyl sulfoxide remaining in the organic solvent solution into an aqueous phase, thus giving an organic solvent solution which is substantially free from dimethyl sulfoxide; and (iii) recovering the sucrose fatty acid ester from the organic solvent solution.

Подробнее
31-10-2018 дата публикации

Process for the preparation of compounds useful as inhibitors of sglt2

Номер: KR101913587B1
Принадлежит: 얀센 파마슈티카 엔.브이.

본 발명은 화학식 (V)의 화합물 (여기서, LG 1 은 이탈기이다)을 제1 탄화수소 용매 중에서; 약 -78℃ 내지 약 실온 범위의 온도에서; 아연 염과 유기-리튬 시약의 혼합물과 반응시켜, 상응하는 화학식 (VI)의 화합물 (여기서, M 1 은 리튬이다)과 아연 염의 혼합물을 제공하는 단계; 화학식 (VI)의 화합물과 아연 염의 혼합물에 제1 에테르 용매를 혼합하여, 상응하는 화학식 (VII)의 화합물 (여기서, M 2 는 반응성 아연 화학종이다)을 제공하는 단계를 포함하는 화학식 (I)의 화합물 및 이의 약제학적으로 허용가능한 염 및 용매화물의 신규한 제조 방법에 관한 것이다. The present invention relates to compounds of formula (V) wherein LG & lt ; 1 &gt; is a leaving group in a first hydrocarbon solvent; At a temperature in the range of from about -78 &lt; 0 &gt; C to about room temperature; Reacting a mixture of a zinc salt and an organo-lithium reagent to provide a mixture of the corresponding compound of formula (VI) wherein M 1 is lithium and a zinc salt; (I) comprising mixing a first ether solvent with a mixture of a compound of formula (VI) and a zinc salt to provide a corresponding compound of formula (VII), wherein M &lt; 2 &gt; is a reactive zinc species. &Lt; / RTI &gt; and pharmaceutically acceptable salts and solvates thereof.

Подробнее
11-06-1987 дата публикации

Production of maltose derivative

Номер: JPS62129291A

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
04-11-2022 дата публикации

Single tin organic compound, preparation method and application thereof

Номер: CN112771058B
Принадлежит: Anhui Jinhe Industrial Co Ltd

本申请提供一种单锡有机化合物,用于合成蔗糖‑6‑羧酸酯,所述化合物为下述式(1)表示的化合物:式(1) 其中,R 1 、R 2 和R 3 分别独立地表示C1~C8的直链或支链饱和烷基、C2~C8的直链或支链不饱和烷基、C3~C8的取代或未取代的饱和环烷基、C3~C8的取代或未取代的不饱和环烷基、或C6~C12的芳基或取代芳基;R 4 表示C1~C6的直链或支链饱和烷基或C6~C12的芳基或取代芳基。本申请的单锡有机化合物,使得在合成蔗糖‑6‑羧酸酯过程中,能够准确地进行计量加料,同时提高催化剂回收率、减少后续氯化副反应的发生,且反应较快、能耗小、单位体积内收率更高。

Подробнее
23-06-1999 дата публикации

Process for producing sucrose fatty acid ester

Номер: CN1043767C
Принадлежит: Mitsubishi Chemical Corp

一种制造蔗糖脂肪酸酯的方法,其中由蔗糖与脂肪酸烷基酯在碱催化剂存在下用二甲亚砜作为反应溶剂进行反应得到的反应混合物中分离回收蔗糖脂肪酸酯,所述的方法包括:(1)用一种几乎不与水混溶的有机溶剂和水作为萃取剂,并将水相的pH值调节到3至7.5,对上述反应混合物进行第一次液-液萃取,(2)采用逆流式系统,用水对在第一次液-液萃取中作为有机溶剂相得到的含蔗糖脂肪酸酯的有机溶剂溶液进行第二次液-液萃取;和(3)从有机溶剂溶液中分离回收蔗糖脂肪酸酯。

Подробнее
14-07-2016 дата публикации

Improved cottonseed oil and uses

Номер: AU2009273754B2

The present specification relates to the production of cotton plants and seeds and oil prepared therefrom having elevated levels of oleic and reduced levels of palmitic and linoleic acids. Furthermore, cottonseeds having low levels of cyclopropane and/or cyclopropene fatty acids and/or reduced levels of gossypol are described herein. The specification also describe FatB and CPA-FAS nucleotide and amino acid sequences derived from cotton facilitating,

Подробнее
17-04-2018 дата публикации

Composition and its preparation method suitable for treating nephropathy

Номер: CN107913263A
Принадлежит: Complexa Inc

本文提供经活化脂肪酸、包括经活化脂肪酸的医药组合物、使用经活化脂肪酸用以治疗肾病变的方法和制备经活化脂肪酸的方法。

Подробнее
16-09-2004 дата публикации

Novel-chemical entities and methods for their use in treatment of metabolic disorders

Номер: CA2517929A1

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to produce an improvement in cognitive ability.

Подробнее
10-02-2014 дата публикации

Extruded polymer foams containing sugar esters and brominated fatty acid as flame retardant additive

Номер: RU2506289C2

FIELD: chemistry. SUBSTANCE: invention relates to a combustion resistant mixture. The mixture contains at least one combustible polymer or a copolymer of a styrene monomer and hexa-, hepta- or octa ester of sucrose and a mixture of brominated C 16 -C 18 fatty acids or a mixture of such esters. Also disclosed is a method of endowing the combustible polymer or styrene monomer copolymer with flame retardant properties. EFFECT: invention provides excellent flame retardation of combustible polymers. 6 cl, 2 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 506 289 (13) C2 (51) МПК C08L C08K C09K C08J C08J C07H 25/06 5/10 21/08 9/06 9/228 13/06 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ Приоритет(ы): (30) Конвенционный приоритет: 31.10.2008 US 61/109,953 (73) Патентообладатель(и): ДАУ ГЛОБАЛ ТЕКНОЛОДЖИЗ ЭлЭлСи (US) (43) Дата публикации заявки: 10.12.2012 Бюл. № 34 2 5 0 6 2 8 9 (45) Опубликовано: 10.02.2014 Бюл. № 4 (56) Список документов, цитированных в отчете о поиске: US 4705690 A, 10.11.1987. US 3359220 A, 19.12.1967. SU 699109, 17.07.1978. RU 2000113443 A, 27.04.2002. 2 5 0 6 2 8 9 R U (86) Заявка PCT: US 2009/060749 (15.10.2009) C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 31.05.2011 (87) Публикация заявки РСТ: WO 2010/051163 (06.05.2010) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. Е.Е.Назиной (54) ЭКСТРУДИРОВАННЫЕ ПОЛИМЕРНЫЕ ПЕНЫ, СОДЕРЖАЩИЕ СЛОЖНЫЕ ЭФИРЫ САХАРА И БРОМИРОВАННОЙ ЖИРНОЙ КИСЛОТЫ, В КАЧЕСТВE ДОБАВКИ, ИНГИБИРУЮЩЕЙ ВОСПЛАМЕНЕНИЕ смесь таких сложных эфиров. Также предложен способ придания ингибирующих воспламенение свойств горючему полимеру или сополимеру стирольного мономера. Изобретение позволяет обеспечить превосходное ингибирование воспламенения горючих полимеров. 2 н. и 4 з. п. ф-лы, 2 пр. (57) Реферат: Изобретение относится к смеси, устойчивой к горению. ...

Подробнее
15-06-1976 дата публикации

Synthesis of higher polyol fatty acid polyesters

Номер: US3963699A
Принадлежит: Procter and Gamble Co

A solvent-free transesterification comprising the steps of (1) heating a mixture of a polyol, a fatty acid lower alkyl ester, an alkali metal fatty acid soap, and a basic catalyst to form a homogenous melt; and (2) subsequently adding to the reaction product of step (1) excess fatty acid lower alkyl esters yields polyol fatty acid polyesters.

Подробнее
21-05-1985 дата публикации

Synthesis of higher polyol fatty acid polyesters using high soap:polyol ratios

Номер: US4518772A
Автор: Robert A. Volpenhein
Принадлежит: Procter and Gamble Co

An improved solvent-free transesterification process for producing higher polyol fatty acid polyesters is disclosed. In this process a mixture of a polyol, a fatty acid methyl, 2-methoxy ethyl or benzyl ester, an alkali metal fatty acid soap, and a basic catalyst, having a molar ratio of soap:polyol of from about 0.6:1 to about 1:1, preferably from about 0.75:1 to about 1:1, is heated to form a homogeneous melt. To this melt is subsequently added excess fatty acid methyl, 2-methoxy ethyl or benzyl ester, yielding the desired polyol fatty acid polyesters.

Подробнее
10-01-1989 дата публикации

Compositions containing novel solid, nondigestible, fat-like compounds

Номер: US4797300A
Принадлежит: Procter and Gamble Co

Plastic shortening and other food compositions which comprise an edible oil and a fatty acid ester of sucrose wherein the fatty acid groups consist essentially of short chain fatty acid radicals containing from 2 to 10 carbon atoms and long chain fatty acid radicals containing from 20 to 24 carbon atoms in a molar ratio of short chain:long chain radicals of 5:3 to 3:5, the said esters having a degree of esterification of about 7 to 8. The edible oil can be a triglyceride oil or a nondigestible oil.

Подробнее
26-04-1994 дата публикации

Solid, nondigestible, fat-like compounds and food compositions containing same

Номер: US5306514A
Принадлежит: Procter and Gamble Co

Fatty acid esters of polyols having at least 4 hydroxyl groups wherein the fatty acid groups consist essentially of: (1) long chain unsaturated fatty acid radicals containing at least 12 carbon atoms or mixtures of said unsaturated radicals with saturated fatty acid radicals containing 2 to 12 carbon atoms, and (2) long chain saturated fatty acid radicals containing at least 20 carbon atoms, wherein the molar ratio of (1):(2) is from 1:15 to 2:1 and wherein at least 4 of the hydroxyl groups of the polyol are esterified. The compounds are useful as nondigestible substitutes for solid fats in foods.

Подробнее
23-10-2020 дата публикации

Dextrin fatty acid ester and cosmetic

Номер: CN107428790B
Автор: 加藤大亮, 铃木拳直
Принадлежит: Chiba Flour Milling Co Ltd

在糊精脂肪酸酯中,糊精的平均糖聚合度为3以上且100以下。脂肪酸由碳数为14以上且18以下的一种以上直链饱和脂肪酸和碳数为14以上且18以下的一种以上支链饱和脂肪酸组成。脂肪酸中的直链饱和脂肪酸的摩尔分数为0.75以上且0.95以下,每葡萄糖单元的所述脂肪酸的平均取代度为1.5以上且2.0以下。

Подробнее
01-12-1998 дата публикации

Novel solid nondigestible fat-like compounds and food compositions containing same

Номер: KR0168682B1

본 발명은, 지방산 그룹이 필수적으로 (1) 적어도 12개의 탄소원자를 함유하는 장쇄 불포화 지방산 라디칼 또는 상기 불포화 라디칼과 2 내지 12개의 탄소원자를 함유하는 포화 지방산 라디칼의 혼합물, 및 (2) 적어도 20개의 탄소원자를 함유하는 종쇄 포화 지방산 라디칼로 이루어지며, (1):(2)의 몰비가 1:15 내지 2:1이고, 폴리올의 하이드록실 그룹중 적어도 4개가 에스테르화되는, 4개 이상의 하이드록실 그룹을 갖는 폴리올의 지방산 에스테르를 개시한다. 상기 혼합물은 식품에 고체 지방의 비소화성 대용품으로 유용하다. The present invention is directed to a fatty acid group consisting essentially of (1) a long chain unsaturated fatty acid radical containing at least 12 carbon atoms or a mixture of said unsaturated radical and a saturated fatty acid radical containing 2 to 12 carbon atoms, and (2) at least 20 carbon sources 4 or more hydroxyl groups, consisting of a long chain saturated fatty acid radical containing a sugar, wherein the molar ratio of (1) :( 2) is from 1:15 to 2: 1 and at least 4 of the hydroxyl groups of the polyol are esterified; Fatty acid esters of polyols having The mixture is useful as a non-digestible substitute of solid fats in foods.

Подробнее
14-10-2004 дата публикации

Polymerizable monomers and process of preparation thereof

Номер: WO2004087725A1

The present invention relates to polymerizable monomers for applications in medicine and biotechnology and synthesis thereof. The polymerizable ligands containing NAcetyl Glucosamine bind more strongly to lysozyme than NAG itself. The binding is further enhanced when a spacer arm, for example 6- Amino Caproic Acid (6-ACA) is introduced in the structure. The conjugated ligands could be used for prevention and treatment of bacterial and viral infections. Moreover these ligands can be coupled to stimuli sensitive polymers and used for the recovery of biomolecules. The methodology can be extended to other ligands such as sialic acid and the corresponding polymers used for preventilIg influenza and for rotavirus infections.

Подробнее
06-05-2014 дата публикации

Cottonseed oil and uses

Номер: US8716555B2

The present specification relates to the production of cotton plants and seeds and oil prepared therefrom having elevated levels of oleic and reduced levels of palmitic and linoleic acids. Furthermore, cottonseeds having low levels of cyclopropane and/or cyclopropene fatty acids and/or reduced levels of gossypol are described herein. The specification also describe FatB and CPA-FAS nucleotide and amino acid sequences derived from cotton facilitating, inter alia the direct modification of plant oil content and/or composition.

Подробнее
16-06-2015 дата публикации

Cottonseed oil and uses

Номер: US9057075B2

The present specification relates to the production of cotton plants and seeds and oil prepared therefrom having elevated levels of oleic and reduced levels of palmitic and linoleic acids. Furthermore, cottonseeds having low levels of cyclopropane and/or cyclopropene fatty acids and/or reduced levels of gossypol are described herein. The specification also describe FatB and CPA-FAS nucleotide and amino acid sequences derived from cotton facilitating, inter alia the direct modification of plant oil content and/or composition.

Подробнее
10-01-2015 дата публикации

Lipochitooligosaccharides stimulating arbuscular-mycorhisal symbiosis

Номер: RU2539028C2

FIELD: chemistry. SUBSTANCE: group of inventions relates to application of lipochitooligosaccharide of formula for stimulation of plant mycorhisation, where n=2 or 3, R 1 represents lipid substituent, which represents fatty acid chain, containing from 16 to 18 carbon atoms, which can be saturated or mono- or di-unsaturated, and R 2 represents H or SO 3 H. Also claimed is mixture of lipochitooligosaccharides for stimulation of arbuscular-mycorhisal plant symbiosis, for stimulation of plant seed germination or for stimulation of plant seed germination or for stimulation of plant root system development and containing in effective amount lipochitooligosaccharide of formula (I), where R 2 represents H, and lipochitooligosaccharide of formula (I), where R 2 represents SO 3 H. EFFECT: group of inventions effectively stimulates plant seed germination, of arbuscular-mycorhisal plant symbiosis and plant root system development. 9 cl, 16 dwg, 9 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 539 028 C2 (51) МПК A01N 63/04 (2006.01) C07H 13/06 (2006.01) A01H 17/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011114866/10, 28.10.2009 (24) Дата начала отсчета срока действия патента: 28.10.2009 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 10.12.2012 Бюл. № 34 (45) Опубликовано: 10.01.2015 Бюл. № 1 C 2 C 2 and tri-iodobenzoic acid stimulate mycorrhizal colonization and affect carbohydrate partitioning in mycorrhizal roots of Lablab purpureus // New Phytol. (1997), 139, 361-366. LUM M.R. ET AL. Roots and their symbiotic microbes: strategies to obtain nitrogen and phosphorus in a nutrient-limiting environment // J. Plant (см. прод.) (73) Патентообладатель(и): ИНСТИТЮ НАСИОНАЛ ДЕ ЛЯ РЕШЕР АГРОНОМИК (FR), СЕНТР НАСИОНАЛ ДЕ ЛЯ РЕШЕРШ САЕНТИФИК (FR), УНИВЕРСИТЭ ПОЛЬ САБАТЬЕ (ТУЛУЗА III) (FR) (85) Дата начала рассмотрения заявки PCT на национальной фазе: 30.05.2011 2 5 3 9 0 2 8 (86) Заявка ...

Подробнее
25-06-2019 дата публикации

Chitosamine derivative, its composition and its medical usage

Номер: CN109929001A
Принадлежит: (suzhou) Medical Technology Co Ltd

本发明提供式(A)化合物及其药学上可接受的盐和酯,以及其药物组合物,所述化合物及其药物组合物在用于制备预防或治疗哺乳动物关节及骨骼疾病如关节炎及骨质疏松症的药物中的用途。

Подробнее
06-11-2018 дата публикации

Glycosylation tetravalence platinum-like compounds with active anticancer, preparation method and application

Номер: CN105622673B
Автор: 王庆鹏, 王欣, 王鹏
Принадлежит: Nankai University

具有抗癌活性的糖基化四价铂类化合物、制备方法及应用,本发明创造首次将糖基基团引入四价铂母核,设计合成了一系列新型糖基化修饰四价铂类化合物,考察了其抗癌、抗肿瘤能力;这一系列原始创新性研究,有望获得对多种对肿瘤有效的先导分子,为解决传统二价铂类药物存在的缺陷提供新候选药物分子,也为四价铂类化合物的修饰开辟新的途径;此类源头上创新药物研究,对国民经济和社会发展及人民健康等都将具有重要的理论价值和实际意义。

Подробнее
31-05-1999 дата публикации

A process for making high purity fatty acid lower alkyl esters

Номер: AU1298799A
Принадлежит: Procter and Gamble Co

Processes for the synthesis of high purity fatty acid lower alkyl esters comprise the steps of: (a) converting a fatty acid source to a product mixture comprising lower alkyl esters and by-products; (b) water-washing the product mixture at elevated temperature and elevated pressure to remove by-products; and (c) fractionally distilling the water-washed product mixture to obtain high purity fatty acid lower alkyl esters. At least a portion of the fatty acids have from about 20 to about 24 carbon atoms. The high purity lower alkyl esters have an acid value no greater than about 1.0.

Подробнее
28-08-2020 дата публикации

Industrial refining method of sucrose-6-acetate

Номер: CN111592574A
Принадлежит: Anhui Jinhe Industrial Co Ltd

本发明涉及一种蔗糖‑6‑乙酸酯工业精制方法,包括以下步骤:1)三氯蔗糖生产得到的蔗糖‑6‑乙酸酯浓缩液,在40‑70℃温度下溶解到醋酸和醋酐混合溶剂中,蔗糖‑6‑乙酸酯浓缩液与混合溶剂质量比为1:1‑3;2)降温至‑20至10℃结晶分离得到蔗糖‑6‑乙酸酯湿精品及其母液;3)在温度50至90℃之间、负压控制在‑0.05至‑0.1MPa条件,烘干蔗糖‑6‑乙酸酯湿精品、回收湿精品中醋酸及醋酐混合溶剂,得到合格的蔗糖‑6‑乙酸酯精品。发明优点在于:避免了粗品蔗糖‑6‑乙酸酯浓缩液中其他酯类参与后续反应,减少了原料消耗,降低三氯蔗糖生产成本;提高了后续反应收率以及后续分离难度,生产效率大幅度提高;减少污染。

Подробнее
27-07-2016 дата публикации

Compounds and compositions with polyglycerol

Номер: RU2592787C2

FIELD: chemistry. SUBSTANCE: invention relates to polyglyceric thickeners and compositions containing polyglyceric thickeners, which can be used in various purposes, including hygiene of human body. Compositions include one or more compounds containing node structure of 4 to 12 carbon atoms, one or more groups of (poly)glycerol, and one or more hydrophobic functional groups. At that, each of (poly)glycerol groups is connected to nodal structure through first primary binding group, one or more hydrophobic functional groups independently are connected either to nodal structure through primary binding group, or to one of (poly)glycerol groups through secondary binding group. Polyglyceric thickener therein is characterised by glycerol polymerisation degree from more than 3 to approximately 11, and average number of hydrophobic groups per primary binding group is 0.35 or more. EFFECT: invention allows to create thickeners and related compositions, containing more natural or renewable components. 15 cl, 4 dwg, 11 tbl, 5 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C08J 3/03 C07D 307/02 C08G 63/66 A61K 8/86 A61K 8/72 (13) 2 592 787 C2 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011146124/05, 14.11.2011 (24) Дата начала отсчета срока действия патента: 14.11.2011 Приоритет(ы): (30) Конвенционный приоритет: (73) Патентообладатель(и): ДЖОНСОН ЭНД ДЖОНСОН КОНЗЬЮМЕР КОМПАНИЗ, ИНК. (US) 61/413,712; 13/075,346; 13/075,362; 13/075,377; 13/075,388 (43) Дата публикации заявки: 20.05.2013 Бюл. № 14 (45) Опубликовано: 27.07.2016 Бюл. № 21 2 5 9 2 7 8 7 R U Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) СОЕДИНЕНИЯ И КОМПОЗИЦИИ С ПОЛИГЛИЦЕРИНОМ (57) Реферат: Изобретение относится к полиглицериновым независимо связаны либо с узловой структурой загустителям и составам, содержащим через первичную ...

Подробнее
07-09-2018 дата публикации

Fructose analog use for cancer treatment and combinations thereof

Номер: CN108503676A
Принадлежит: Individual

本发明提供一种可用于的癌症治疗的果糖类似物及其组合物,具有靶向性且对正常细胞影响极小,特别是用于AML和胰腺癌以及具有类似代谢特征的癌症时。本发明中果糖类似物选自2,5‑脱水‑D‑甘露醇和1‑位或6‑位被氨基、烷基或芳基化取代的5‑脱水‑D‑甘露醇衍生物,2,5‑脱水‑D‑甘露醇四乙酸乙酯和2,5‑脱水葡萄糖醇及其类似物。本发明果糖类似物可用于制备治疗癌症药物,可以制备为注射制剂或口服制剂。本发明果糖类似物用于制备治疗癌症药物的用途时,可以将果糖类似物与常规抗癌药物联合使用。本发明果糖类似物可以合并葡萄糖类似物的治疗脏器纤维化的用途。

Подробнее
22-01-1991 дата публикации

Derivatives of monophosphoryl lipid A

Номер: US4987237A
Принадлежит: Ribi Immunochem Research Inc

Novel derivatives of monophosphoryl lipid A and a process for their preparation are provided. The derivatives contain one or more free groups, such as an amine, on a side chain attached to the primary hydroxyl groups of the monophosphoryl lipid A nucleus through an ester group. The derivatives provide a convenient method for coupling the lipid A through coupling agents to various biologically active materials, substrates, and the like, wherein the immunostimulant properties of lipid A are desired.

Подробнее
10-12-2002 дата публикации

Aqueous immunologic adjuvant compostions of monophosphoryl lipid A

Номер: US6491919B2
Автор: R. Thomas Crane
Принадлежит: Corixa Corp

An aqueous adjuvant composition comprising an attenuated lipid A derivative and a non-immunostimulatory surfactant or surfactants enhances the immunological response in a warm blooded animal to a protein antigen. Attenuated lipid A derivatives useful according to the subject invention include monophosphoryl lipid A and 3-O-deacylated monophosphoryl lipid A. A surfactant or mixtures of surfactants are dissolved in a solvent. 1,2 Dipalmitoyl-sn-glycero-3-phosphocholine is a preferred surfactant. The dissolved surfactant is added to an attenuated lipid A derivative to obtain a mixture. The molar ratio of attenuated lipid A derivative to surfactant in the mixture is about 4:1. The solvent is evaporated and water is added to the resulting film. The suspension is sonicated in a 60° C. water bath until it becomes clear. Animals administered the adjuvant formulation exhibited increased antibody responses to a given antigen as well as displayed enhanced lymphocyte proliferative and cytotoxic T-lymphocyte responses. Intranasal administration of the aqueous adjuvant composition and an antigen stimulates the production of serum and mucosal secreted IgA.

Подробнее
11-01-2000 дата публикации

Phosphoglycolipid and methods for its use

Номер: US6013640A
Принадлежит: Ribi Immunochem Research Inc

The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-β-D-glucopyranosyl]-2-[(R)-3-hexadecanoyloxytetradecanoylamino]-D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

Подробнее
24-07-2003 дата публикации

Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds

Номер: US20030139356A1
Принадлежит: Corixa Corp

Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

Подробнее
29-11-2001 дата публикации

Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds

Номер: WO2001090129A2
Принадлежит: CORIXA CORPORATION

Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

Подробнее
13-02-2003 дата публикации

Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)

Номер: US20030031684A1
Автор: D. Snyder, Kent Myers
Принадлежит: Corixa Corp

Herein is disclosed a method for producing lipopolysaccharide (LPS), comprising: (a) growing a culture of a deep rough mutant bacterial strain in a medium; (b) maintaining the culture in stationary phase for at least about 5 hr; (c) harvesting cells from the culture; and (d) extracting LPS from the cells. The method allows for the production of an LPS which can be used to produce a 3-O-deacylated monophosphoryl lipid A (3D-MLA) having at least about 20 mol % of the hexaacyl congener group. Also herein is disclosed a method of extracting lipopolysaccharide (LPS) from a culture of deep rough mutant bacterial strain cells, comprising: (a) extracting the cells with a solution consisting essentially of at least about 75 wt % of an aliphatic alcohol having from 1 to 4 carbon atoms and the balance water, thereby producing cells with reduced phospholipid content; and (b) extracting the cells with reduced phospholipid content with a solution comprising chloroform and methanol, thereby yielding a solution of LPS in chloroform and methanol (CM). This method provides LPS solutions in CM that have reduced phospholipid content and are produced by relatively simple and inexpensive process steps.

Подробнее
15-01-2001 дата публикации

Lipid-A homologs for therapeutic antibody induction and anticancer and antiviral activity: novel monosaccharides and disaccharide intermediates

Номер: KR100278083B1

지질-A에 결합하는 항체를 유발하는데 유용하고, 그람-음성 세균 감염에 대한 보호 면역을 유발하고, 비루스 감염을 막고, 암 성장을 억제하고, 지질-A와 경쟁하여 수용체에 결합하는 화합물을 기재한다. 또한 이들 화합물을 함유하는 조성물을 기재한다. 더우기, 이 화합물에 의해 유발된 항체, 뿐만 아니라 예컨대 패혈증 치료시에 상기 항체의 사용에 관한 것도 개시된다. Described compounds that are useful for eliciting antibodies that bind lipid-A, elicit protective immunity against Gram-negative bacterial infections, prevent viral infection, inhibit cancer growth, and compete with lipid-A to bind to receptors do. Also described are compositions containing these compounds. Furthermore, disclosed are the antibodies directed by this compound, as well as the use of such antibodies, such as in the treatment of sepsis.

Подробнее
25-08-2014 дата публикации

Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals

Номер: KR20140103150A
Принадлежит: 사노피

본 발명은 화학식 I의 치환 이소티아졸로[5,4-b]피리딘-2-카복사미드 (화학식에서, R1, R2, R3, R10, R11 및 X는 청구범위에 정의된 것과 같음)에 관한 것이다. 화학식 I의 화합물은 트랜스글루타미나제의 억제제, 특히 트랜스글루타미나제 2(TGM2)의 억제제이며, 예를 들면, 골관절염과 같은 퇴행성 관절증 등 다양한 질환의 치료에 적합하다. 본 발명은 또한 화학식 I의 화합물의 제조 방법, 약제로서의 상기 화합물의 용도, 및 상기 화합물을 포함하는 약학적 조성물에 관한 것이다.

Подробнее
26-03-2014 дата публикации

Extruded polymer foams containing esters of a sugar and a brominated fatty acid as a flame retardant additive

Номер: CN102197042B
Принадлежит: Dow Global Technologies LLC

糖和溴化脂肪酸的酯是有用的可燃性聚合物用FR添加剂。所述溴化FR添加剂出乎意料地在挤出温度稳定,并且对可燃性聚合物提供了优异的阻燃性。

Подробнее
09-04-2021 дата публикации

Method for extracting crocin from gardenia

Номер: CN108558645B
Принадлежит: Wuhan Yashibo Technology Co ltd

本发明提供了一种从栀子中提取藏红花素的方法。从栀子中提取藏红花素的方法:用含酶的酸性水溶液对栀子进行浸提,得到浸提液;所述浸提的温度为30‑60℃,酸性水溶液的pH值为3.0~6.5,所述酶为纤维素酶和果胶酶,酸性水溶液中纤维素酶和果胶酶的浓度分别为1%~3%、1%~3%,酶解时间为1h以内;将料液比调至1:20‑40,温度调至50‑70℃,提取1‑2h,将提取液浓缩至膏状,用大孔吸附树脂吸附然后用水洗脱至流出液澄清,然后用乙醇或乙醇‑水混合液进行洗脱,收集洗脱液。本发明对藏红花素的提取率提高了50%,又减少使用有机溶剂使用量;同时相比水提法,本发明提取周期短,效率高。

Подробнее
25-01-2023 дата публикации

Triterpene saponin analogues

Номер: JP2023012519A

【課題】天然サポニンアジュバントQS-21に代わる、QS-21及びQS-7の類似物であるトリテルペングリコシドサポニン誘導アジュバント、それの合成法、及びそれの中間体を提供する。また、本発明の化合物を含む医薬組成物、並びに感染症の治療及び感染症のための免疫化に上記化合物または組成物を使用する方法も提供する。【解決手段】例えば、図に示される化合物(TQL-1055)及びその合成法である。【選択図】図1

Подробнее
27-03-1997 дата публикации

Lipid analogs or their pharmaceutically acceptable salts

Номер: RU2076107C1

FIELD: organic chemistry. SUBSTANCE: product: lipid analogs of the general formula (I): where: R 1 - OH, ; R 2 - where: R 6 and R 7 - H, F; R 8 - H, OH or tetradecanoyloxy; - tetradecanoyl or R 9 where: R 10 - H, F; R 4 - H, OH, tetradecanoyloxy or 2,2-difluorotetradecanoyloxy; - OH, R< and at least one of groups R 4 and - group R 5 ; R 2 - OH, F at condition that exception of case when at least one of R 3 and R 2 - tetradecanoyl substituted with F or at least one substituent of the group: F, OH, tetradecanoyloxy, or at least one of R 3 and R 4 - tetradecanoyl substituted with at least one fluoro-substituted tetradecanoyloxy-group, or their pharmaceutically acceptable salts. Synthesized compounds were used as immunoregulating and immunostimulating preparations. EFFECT: improved method of synthesis. 6 cl, 4 tbl 41019140Сс ПЧ Го (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ” 2076 107. (51) МПК 13) Сл С 07Н 5/06 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 5052656/04, 09.09.1992 (30) Приоритет: 11.12.1989 УР 1-321153 20.02.1990 УР 2-37339 (46) Дата публикации: 27.03.1997 (56) Ссылки: Сагфопуагае Кезеагсй. спет. 6 (4), 625-638 (1987). Сагропуагае Кезеагсп, 162 (1987), 127-140. (62) Первичная заявка, из которой выделена настоящая: 4830600/04 (71) Заявитель: Санкио Компани Лимитед (.Р) (72) Изобретатель: Масао Сиозаки[Р], Нобору Исида[Р], Томово Кобаяси[/Р], Тетсуо Хираока[/Р], Масами Араи[/Р], Юзуру Акаматсу[/Р], Масахиро Нисидзима[/Р] (73) Патентообладатель: Санкио Компани Лимитед (Р) (54) АНАЛОГИ ЛИПИДА ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ (57) Реферат: Использование: В иммунорегулирующих и иммуностимулирующих препаратов. Сущность: продукт: аналоги липида общей формулы |: качестве 1 сн о 5 2 52 = с с 4 2 Е и в \ нк | з ОЕ 6 о Е 1 и 2 | Е -он, 0-Р-ОН к -с-с -Сн-<СН,>, -Сн, | и [3 15 он о Е Е ле Вби В’- НЕ В _Н ОН или тетрадеканоилокси, КЗ - тетрадеканоил или _-С-СН-СН -ССН —_СН и 1з 10 2 10 3 ов Е де В? - Н, Е В - Н; ОН ПРИЕМЛЕМЫЕ СОЛИ ...

Подробнее
08-07-2022 дата публикации

Glucosamine derivative, composition thereof and medical application thereof

Номер: CN109929001B
Принадлежит: Risen Suzhou Pharma Tech Co Ltd

本发明提供式(A)化合物及其药学上可接受的盐和酯,以及其药物组合物,所述化合物及其药物组合物在用于制备预防或治疗哺乳动物关节及骨骼疾病如关节炎及骨质疏松症的药物中的用途。

Подробнее
28-09-2016 дата публикации

Polyglyceryl compounds and compositions

Номер: CN102558541B

本发明提供了包含一种或多种化合物的组合物,所述化合物的结构包含:具有4至12个碳原子的节点结构、一个或多个(聚)甘油基基团、以及一个或多个疏水部分,其中所述一个或多个(聚)甘油基基团的每一个都通过第一初级连接基连接到所述节点结构上,所述一个或多个疏水部分各自独立地通过初级连接基连接到所述节点结构上或通过次级连接基连接到所述(聚)甘油基基团之一上,并且其中所述聚甘油基增稠剂的平均甘油基聚合度大于3至小于约11,以及每个初级连接基的平均疏水基团数为约0.35或更大。本发明还提供了聚甘油基化合物,包含水、表面活性剂和聚甘油基增稠剂的组合物,以及制备本发明的聚甘油基化合物和组合物的方法。

Подробнее